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The Value of Targeted Therapies in Lung Cancer 
 
Abstract 
 
The goal of this dissertation was to examine the realized value of targeted 
therapies in routine care and to identify opportunities for improving the return on medical 
spending for these technologies. 
  Chapter 1 investigated the value of targeted therapies in lung cancer patients 
who were treated in routine care.   This observational, claims-based analysis used 
propensity score, and instrumental variable methods, combined with a Kaplan Meier 
Sample Average estimator to calculate lifetime costs and life expectancy.  An 
incremental comparison showed that the realized value of targeted therapies in routine 
care was unfavorable relative to chemotherapy treatment.  Subgroup analyses revealed 
that initial erlotinib therapy yielded effectiveness results that are substantially lower than 
efficacy survival outcomes in molecularly guided trials.   Our results indicated that in 
routine care, chemotherapy was the most cost effective strategy.  The unexpectedly low 
outcomes with first-line erlotinib suggested that some of the value of this treatment was 
not being realized in practice.     
  Chapter 2 examined the practice patterns of targeted therapies and utilization of 
predictive biomarker testing in routine care to better understand the observed gaps 
between trial-based and ‘real-world’ outcomes with these agents.   In our nationally 
representative cohort of lung cancer patients, we found that the vast majority of patients 
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did not undergo molecular testing to inform first-line therapy.    Our prediction models for 
biomarker screening and first-line treatment suggested that phenotypic enrichment 
criteria guided selection for testing and initiation of erlotinib therapy.   Since clinical 
characteristics do not adequately discriminate between mutation positive and wild type 
tumors, these practices signal the need for wider dissemination of biomarker screening 
to accurately target patients towards improving therapeutic gains with erlotinib. 
  Chapter 3 assessed the cost-effectiveness of multiplexed predictive biomarker 
screening to inform treatment decisions in lung cancer patients.  Using a micro-
simulation model to evaluate the incremental value of molecularly guided therapy 
compared to chemotherapy in unselected patients, we found that personalized therapy 
is a cost effective strategy.   Our results indicated that better value of targeted therapies 
in lung cancer is achievable through molecularly guided treatment. 
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Chapter 1  The Value of Targeted Therapy in Lung Cancer:  An Observational 
Analysis of Elderly Medicare Population 
1.1  Introduction 
The burden of lung cancer is large both in terms of its impact on those afflicted 
by the disease and in economic terms.  Lung cancer is the leading cause of cancer-
related mortality, with 160,000 deaths estimated to occur nationwide in 2014, which 
represents 27% of all cancer deaths.[1] In 2010, medical spending for cancer reached 
$125 billion, with 10% attributable to lung cancer care alone. Over the next decade, 
these costs are projected to grow by 27% taking into account only the aging of the 
population.[2]  Structural changes such as technology advances will put further 
inflationary pressure on the growing costs for cancer care.   
The introduction of targeted therapies in the treatment of advanced non-small cell 
lung cancer (NSCLC) represents an innovation that has profoundly changed the 
landscape of prognosis in select patients, but these treatments come with a high price 
tag.[3-5]  The two targeted therapies that gained approval by the Federal Drug 
Administration (FDA) for treatment of patients with locally advanced or metastatic 
NSCLC before 2013 are bevacizumab and erlotinib.  The latter is an orally administered 
epidermal growth factor tyrosine kinase inhibitor (EGFR TKI).[6]  It has demonstrated a 
remarkable efficacy in patients whose tumors harbor EGFR drug sensitizing mutations 
compared to chemotherapy alone, with median progression free survival (PFS) of 9.4 
vs. 5.2 months (p-value <0.0001).[7]  The role of EGFR mutations as a predictive 
biomarker for response to erlotinib has been clearly elucidated, but in practice, 
2	  
molecular screening is widely underutilized.[8, 9]  Bevacizumab was approved  for 
initial treatment of advanced, non-squamous NSCLC, based on a phase III randomized 
clinical trial (ECOG 4599), which demonstrated a statistically significant but clinically 
modest median overall survival (OS) benefit of 2 months compared to chemotherapy 
alone.[10, 11]   Trial-based results, however, may not be directly generalizable to the 
majority of patients who are treated in the community, since trials are conducted under 
strictly controlled protocols to increase the internal validity of findings.  Patients treated 
in clinical trials generally constitute a highly selected, healthier and younger group 
compared to the general lung cancer population.[12, 13]  Case in point is a recent 
analysis of non-trial patients with advanced NSCLC, which compared survival 
outcomes of carboplatin and paclitaxel chemotherapy combination with and without the 
addition of bevacizumab.  Unlike the earlier ECOG trial findings, this observational 
analysis of an elderly patient cohort indicated no significant OS benefit for the 
bevacizumab combination (hazard ratio of 1.01 (95% CI, 0.89-1.16)).[11, 14]   
There is an increasing awareness among the oncology community and policy 
makers that while some targeted therapies hold the promise of substantial outcome 
improvements in cancer, they are associated with high costs.   Bevacizumab costs 
$7,400 for a 3-week cycle to treat an average patient.[15]  The corresponding cost for 
erlotinib is around $3,400.[16]  While the acquisition costs for these drugs are high,  it is 
important to examine not just the costs of the drug but also the total costs associated 
with management of patients who receive these therapies, in tandem with the 
outcomes.  Traditional economic analyses that estimate the value of medical 
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interventions to inform decision-makers have been based on efficacy data from trials.   
To date, the cost-effectiveness of both erlotinib and bevacizumab in NSCLC has been 
evaluated using these efficacy endpoints.[17, 18]    In contrast, an evaluation based on 
routine care that incorporates contemporary practice patterns and effectiveness 
outcomes may help illuminate the actual realized value of these innovations.  Such a 
population based analysis may help inform decisions surrounding translational research 
funding and coverage policies. 
To assess the value of targeted therapies in routine care, we compared the 
relative cost effectiveness of management with best supportive care (BSC) versus 
treatment with chemotherapy alone or with targeted therapy among patients with 
advanced NSCLC.  The analysis was done from a payer perspective in the United 
States using a lifetime horizon.    
1.2  Methods 
1.2.1  Data Sources 
We used data from the National Cancer Institute’s Surveillance, Epidemiology, 
and End Results (SEER) program linked to Medicare claims.  The SEER program 
collects information from 17 cancer registries, which cover  approximately 28% of the 
US population.[19]  SEER captures information on cancer sites, histology, stage, grade, 
and dates of diagnosis and death, as well as patient demographic characteristics for all 
persons diagnosed with a cancer residing in one of the cancer registries.   SEER data 
for patients with diagnoses from January 1, 2007 through December 31, 2009, matched 
to Medicare claims data from January 1, 2006, through December 31, 2010 were 
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available for patients with fee-for-service (FFS) coverage.  Information from claims for 
inpatient and outpatient hospital, skilled nursing facility, home health agency, and 
hospice care, as well as physician services, prescription drugs and durable medical 
equipment was included in the analysis.   
1.2.2  Study participants 
Patients with pathologically confirmed non-squamous, stage IV NSCLC 
diagnosed between January 1, 2007 and December 31, 2009 were included.  Stage at 
diagnosis based on the SEER derived staging algorithms was used to identify patients 
with advanced disease.  To increase the homogeneity of patients, we excluded patients 
who underwent primary cancer surgery.[20]  Patients were also excluded if they had 
other cancers diagnosed either before or after the index NSCLC diagnosis (to avoid 
chemotherapy misclassification bias).   Patients enrolled in either a health maintenance 
organization (HMO), or only in part A or B Medicare at any time during the observation 
period, starting 12 months prior to diagnosis and ending at death or last follow up, were 
excluded to ensure a complete history of claim records.  The primary comparison 
groups were based on receipt of any targeted therapy (bevacizumab, erlotinib), with or 
without chemotherapy, starting from index diagnosis (Figure 1.1).  Specifically, we 
compared three groups: 1) targeted treatment group, which comprised of patients who 
were treated with bevacizumab or erlotinib, with or without chemotherapy, at some point 
after diagnosis of stage IV NSCLC ; 2) chemotherapy group, consisting of patients who 
received chemotherapy alone and no targeted therapy at any point after diagnosis; 3) 
remaining patients  were categorized to the best supportive care (BSC) group, if there 
was no evidence of systemic therapy receipt (chemotherapy or targeted therapy).   
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Figure 1.1. Flow diagram of study cohort 
NSCLC, non-small cell lung cancer  
†targeted therapy includes bevacizumab and erlotinib 
1.2.3 Treatment Classification 
We identified systemic therapy use from Medicare claims.  Claims for individual 
drugs and therapy administration were flagged using International Classification of 
Disease Version 9 (ICD-9) diagnostic and procedure codes, and the diagnosis related 
group (DRG) codes in the inpatient hospital files.  Healthcare Common Procedure 
Coding System codes (HCPCS) and National Drug Codes (NDC) were used to identify 
systemic therapy administration in the outpatient, physician, durable medical equipment 
and Medicare Part D files using previously described methods.[21, 22]    
26	  427	  Pa.ents	  diagnosed	  with	  
non-­‐squamous	  stage	  IV	  NSCLC	  
between	  2007-­‐2009	  
5	  260	  managed	  with	  
best	  suppor.ve	  care	  
3	  191	  treated	  with	  	  
chemotherapy	  alone	  
1	  834	  	  treated	  with	  targeted	  
therapy	  ±	  chemotherapy†	  
16	  142	  	  	  Excluded	  
5389	  Age	  at	  diagnosis	  <66	  y	  
2225	  Not	  pathologically	  conﬁrmed	  
2878	  Not	  eligible	  for	  Medicare	  Part	  A	  
and	  B	  
5212	  Enrolled	  in	  Medicare	  HMO	  
	  438	  	  Primary	  cancer	  surgery	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1.2.4  Life expectancy 
The primary health outcome was life expectancy, which was estimated from 
index diagnosis of stage IV NSCLC to date of death or censoring.  We used information 
reported in the Medicare files on death dates from any cause, which were 
administratively censored for survival outcomes on 12/31/2011.  At the end of follow up, 
only a small proportion of patients were censored, ranging from 2.1% in the BSC group 
to 6.7% in the target therapy treatment group.  Survival time after the first year from 
diagnosis was discounted using a 3% annual rate.[23] 
1.2.5  Costs 
Our economic outcome of interest was lifetime spending.  Total costs for each 
participant were calculated by summing the Medicare Part A, B and D reimbursements, 
primary insurance payments and patient-liability costs (deductibles and co-payments 
that are the patient’s responsibility).[24]  Costs were expressed in real terms, in 2013$, 
by adjustment for general price inflation using the GDP Deflator, a measure of price 
inflation over time for all goods and services in the economy.[25]  Costs incurred after 
one year from diagnosis were discounted using a 3% annual rate.[23] 
1.2.6  Phases of care 
Since costs of cancer care tend to exhibit a U shaped distribution over time 
(Appendix) and the entire cost histories are not observed for censored cases, we 
partitioned costs into three phases: initial, continuing, and terminal.  This approach 
utilizes all information for participants who contribute data for a particular period.   Thus, 
histories of long- and short-time survivors are represented in this calculation.  The 
phase-specific approach can be used to estimate lifetime costs for incident cases that 
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are cumulative from date of diagnosis to death by combining phase-specific cost 
estimates with survival models when the entire cost history is not observed.[26]   
The length of each phase was based on observed U-shaped patterns of costs 
over time (Appendix).   Accordingly, we defined the duration of the initial phase as the 
month of diagnosis and the following 2 months The terminal phase comprised the last 3 
months of life, and the continuing phase as the remainder of the time and was therefore 
of variable duration.   The initial phase captures the primary course of therapy.  The 
continuing phase includes surveillance activities for detecting and treating recurrences.  
The terminal phase applies to care received at the end of life.  Cost data were 
partitioned into 3-monthly intervals from diagnosis.  A hierarchy was used to allocate the 
observation time to costing phases.  Among patients who died, costs were first assigned 
to the terminal phase, then to the initial period, and any remaining time to the continuing 
period.  Among censored patients, costs were assigned to the initial phase first then any 
costs incurred in the remaining time were categorized as the continuing phase.   
1.2.7  Patient Characteristics 
Characteristics expected to be related to treatment selection and some that may 
also potentially affect the outcomes of interest were identified for analytic strategies to 
reduce selection bias.[27]  Socio-demographic and clinical characteristics included age, 
gender, race/ethnicity, marital status, US census tract level education and income, 
histology, presence of brain metastases, proxy indicator for acculturation using zip code 
level proportion of population who were born outside of the US, enrolment in Medicaid, 
and urban residence.  Factors that may influence access to treatment included whether 
the patient was treated in a teaching hospital, census tract-level managed care 
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penetration, hospital bed and physician density (per 100,000 inhabitants), hospital 
referral region (HRR), and year of diagnosis.   Hospital referral regions (HRR) were 
developed by Dartmouth Atlas of Health Care based on referral patterns to hospitals for 
Medicare patients.  These regions represent areas with similar practice patterns.[28]  
There are 81 HRRs represented in the SEER regions in 2007.  Patients were assigned 
to their HRR based on their residence zip code at the time of diagnosis of NSCLC.   We 
calculated a comorbidity score that combines the conditions in the traditionally 
employed Charlson and Elixhauser indices using the method described by Gagne, et 
al.[29]   We modified the score by excluding cancer conditions (Dr. Joshua Gagne, 
personal communication).  The combined score has demonstrated a higher accuracy in 
predicting mortality in elderly patients using an external validation dataset compared to 
the individual indices.  In addition, the combined score uses weights from more recent 
data and it reflects changes in prognosis of diseases stemming from improvements in 
medical care.[29] Each of the 18 conditions included in the combined score were further 
coded as indicator variables.  Proxy measures of patient health and performance status 
at baseline included inpatient length of stay within one year prior to diagnosis, use of 
skilled nursing and home health care services, use of home oxygen and activities of 
daily living (ADL) aids (walkers, wheelchairs, hospital beds), as well as pre-diagnosis 
medical costs.[30]  Claims starting from 12 months to 2 months prior to diagnosis were 
used for derivation of comorbidity scores,  pre-diagnosis costs and indicators of 
functional status.  The 2 months immediately prior to diagnosis were excluded to avoid 
including claims for treating symptoms of undiagnosed cancer.   
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1.2.8  Statistical Methods Propensity	  Score	  Analysis	  
To balance observed baseline characteristics across treatment groups, we 
constructed a multinomial logistic regression model by regressing treatment (categorical 
variable with 3 levels: BSC, chemotherapy, and targeted therapy) on variables that 
potentially confound the treatment and outcome pathway and baseline covariates 
associated with treatment selection.   The final model included 43 patient and provider 
characteristics.  A weight representing the inverse of the predicted probability of 
treatment (IPW) from the multivariable logistic regression model was calculated for each 
patient.  The conditional predicted probability of treatment is the propensity score (PS).  
We compared the distributions of these characteristics with and without applying IPW.   
To evaluate the quality of the PS weighting, we assessed the balance in baseline 
characteristics across treatment groups using standardized differences - the absolute 
difference in means divided by the pooled standard deviation.  By convention, 
standardized differences of 10% or less are interpreted to signal a ‘good’ balance 
across groups.[27] 
Life	  Expectancy	  
The estimation of life expectancy for the main analysis proceeded in two parts.  
First, an estimate of mean life expectancy was constructed based on the observed data 
(restricted mean).  This was accomplished using a doubly robust estimation method 
which combines inverse probability weighting by propensity score with multivariate 
nonparametric Cox proportional hazard (PH) modeling of the relationship between 
covariates and survival for each treatment group.  We checked the proportionality of 
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hazards assumption by comparing the log-cumulative hazard plots by treatment which 
confirmed that the PH assumption was not violated.  Next, because the aim of the 
analysis was to estimate mean life expectancy over a lifetime horizon and since the 
observed survival curves did not reach a survival probability of zero (albeit, the extent of 
censoring was small, ranging from 2.1% in the BSC group to 6.7% in the target therapy 
treatment group), we opted to use parametric modeling to extrapolate survival beyond 
the observation period (extended means).[31, 32]   First, we fit parametric models 
(Weibull, exponential, log-logistic, log-normal and gamma) to the IPW, adjusted survival 
curve for each treatment group.   The Akaike’s information criterion (AIC) test was used 
to select the model with the best fit.[32]  However, even the best fitting model did not 
appear suitably to fit the IPW, adjusted survival curve.  Hence, a more flexible 
parametric method was adopted.[31] Briefly, we fit piecewise exponential models to the 
IPW, adjusted survival curves for each treatment group (Appendix).  Then we examined 
the kernel-smoothed hazard functions from the Cox PH models (Appendix).  A long-
term stable hazard trend was observed in all treatment groups when the survival 
probability reached 20% and lower.  Using this cut point, the estimated hazard rates 
from the fitted piecewise-exponential models were averaged conditioning on treatment 
group.  The tails of the IPW Cox PH model based survival function were fit using an 
exponential model with the rate parameter estimated using the average hazard rates 
from the piecewise exponential models for each treatment group to project survival 
beyond the observation period (Appendix).[33]  Therefore, the extended mean life 
expectancy for each treatment group was based on a composite survival-function 
11	  
estimator, using the IPW Cox PH based survival function and exponential parametric 
models beyond last follow up.    
Phase-­‐Specific	  Costs	  
We carried out a doubly robust estimation of phase-specific costs in which 
inverse-propensity weighting was combined with regression modeling with baseline 
covariates, including HRR fixed effects, and calendar year.  We modeled phase-specific 
costs using generalized linear models (GLMs) with an Extended Estimating Equations 
(EEE) estimator.[34, 35]  Briefly, the EEE model allows estimation of a flexible mean 
and variance function based on the data, which has been shown to reduce bias and 
increase efficiency compared to user specified parameters.[34]  The semi-parametric 
EEE model can be implemented using the pglm command in STATA, which has been 
constructed by Basu.[35]  This command simultaneously estimates the link and 
variance parameters from the data along with the regression parameters.  All models 
were based on a doubly-robust estimator, with inclusion of IPW and baseline covariates. 
We used robust standard errors clustered at the patient level to account for correlation 
between cost observations for each patient.   Post-estimation procedures were used to 
generate predicted costs.  Both terminal and continuing phase costs depended on 
duration of survival, calendar year, and treatment group (Appendix).   Several functional 
forms (e.g. main effects for time trends and survival length with and without interactions) 
were fit and models were selected based on goodness of fit tests: the Pearson 
correlation test, which tests the correlation between residuals and predicted costs on 
raw scale to determine systematic bias in prediction of costs; the Hosmer-Lemeshow 
test, which evaluates the calibration of predicted means across deciles with sample 
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means.[34, 36]   The models with the best fit  for the phase specific costs had a 
Pearson correlation coefficient ranging from -0.01 to  0.01,  and no systematic patterns 
across deciles of predicted costs. Lifetime	  cost	  estimation	  approach	  
We combined phase-specific cost predictions with survival curves to estimate 
lifetime costs using the Kaplan-Meier Sample Average (KMSA) estimator based on a 
previously proposed approach.[26, 37]  Separate KMSA estimates were calculated for 
each treatment group.  We calculated the sum of a weighted average of predicted 3-
monthly costs over the 4-year period during which Medicare costs data was available.  
The KMSA estimator for expected total spending prior to censoring for costs (December 
31, 2010) is: 
𝐸 = 𝑝! ∗ 𝐸!!!!  
where:   i=3-monthly intervals from diagnosis, range: 1 up to 16, i=1 represents the first 
3 months of diagnosis, 𝑝!= doubly robust, IPW Cox PH probability of surviving to period 
i using SEER-Medicare data, 𝐸! = average modeled cost using EEE estimator incurred 
in period i among participants surviving to this time; costs for participants dying in period 
i are included; costs for participants who were censored in period i are excluded.  This 
part of the KMSA estimator constitutes the restricted mean analysis since it does not 
include extrapolation of costs beyond the date of censoring, on December 31, 2010.  
The restricted mean approach was used in sensitivity analyses to examine the impact of 
modeling specifications on the outcome of interest. 
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Since restricted means would underestimate costs for patients who were alive 
after December 31, 2010, we relied on extrapolated cost predictions to estimate the 
extended mean lifetime spending.    The KMSA estimator for extrapolated costs was 
calculated as follows: 
𝐸∗ = 𝑝!∗ ∗ 𝐸!∗!
where: j=3-monthly period from diagnosis, range: 5 up to 26 (when <0.5% of patients 
remained alive), 𝑝!= fitted survival probability based on the composite survival-function 
estimator, 𝐸!∗  = expected expenditure in period j, s.t. 
𝐸!∗  = 𝑑!   ∗   𝑡 + (1− 𝑑!  ) * 𝑐, 
where: 𝑑!  = rate of dying in period j, 𝑡 = predicted average cost in terminal phase in 
period j , 𝑐 = predicted average cost in continuing phase in period j. 
 The KMSA estimator of expected total cumulative costs is: 
𝐸+𝐸∗ 
This extended mean estimate of lifetime costs was used in the main analysis. 
Cost	  Effectiveness	  Analysis	  
We calculated the incremental cost-effectiveness by first ranking the strategies in 
order of increasing effectiveness.  Strategies that were strongly dominated, i.e., those 
that had a lower effectiveness and higher costs, were eliminated.  Incremental cost 
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effectiveness ratios (ICERs) were calculated for each strategy in relation to the next 
best strategy.  The ICER is a ratio of the difference in lifetime mean costs divided by the 
difference in mean life expectancy.  Strategies with a higher ICER that were less 
effective than another strategy were eliminated by extended dominance.  The ICERs 
were recalculated for the remaining strategies that were not eliminated by either strong 
or extended dominance.[38]  
Subgroup	  analysis	  
To explore the value of first-line treatment with specific targeted therapies in the 
non-trial setting, we selected subgroups of patients who began targeted therapy 
treatment with first line bevacizumab combination therapy, erlotinib alone, or a doublet 
chemotherapy alone.  The date of the first systemic therapy claim within 120 days from 
diagnosis was used to define the start date of first line treatment.[14]  Cancer-directed 
treatments with dates within 29 days from initiation of therapy were flagged for the 
purpose of identifying combination therapies.[20]   We estimated the extended means 
for life expectancy and costs for each group using methods described above.  These 
estimates were adjusted for factors listed in  Table 1.1 and discounted at 3% per 
annum. 
Sensitivity	  Analyses	  
 We conducted several sensitivity analyses of lifetime cost and life expectancy 
estimation using restricted means to evaluate the influence of model specification on 
these outcomes.  These included IPW models with HRR fixed effects and IPW models 
without HRR fixed effects.   
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Instrumental	  Variable	  Methods	  
While PS methods can adjust for observed confounders that bias the 
treatment effect, these methods do not mitigate bias due to unobserved differences in 
known or unknown prognostic factors between the treated and untreated groups and 
across geographic areas.  We investigated 1-year survival probability and costs to 
compare the consistency of results using PS analytic approaches and instrumental 
variable (IV) analyses.  Consistent results across these analytic methods would signal 
that the causal effects were not influenced by omitted variables.    The intuition behind 
IV methods is to compare groups not according to treatment they received, but rather 
according to the likelihood of receiving treatment, the instrument.   The IV has to predict 
treatment choice but cannot be independently associated with the outcome, other than 
through its effect on treatment.[39]   The IV can be regarded as a randomization 
mechanism, therefore, observed and unobserved characteristics should be similar 
across levels of the instrument.  Area-level practice patterns are commonly used in IV 
approaches to adjust for selection bias in health services research.[40-42]  This 
approach accounts for differences between patients across treatment groups, but it 
makes the assumption that potential confounders are randomly distributed across the 
geographic areas.    We further account for possible unobserved confounding at the 
area level by including geographic area fixed effects.  For example, this approach would 
account for the documented significant geographic variation in smoking patterns.[43]  
Smoking not only increases the risk of mortality in cancer patients, but is also correlated 
with predictors of treatment choice and response.[8, 44]  To account for confounders 
both at the patient and area level, we used annual treatment rates within each HRR as 
the IV with fixed area effects to control for fixed unobserved differences between areas.  
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We first divided patients into quintiles according to annual rate of diffusion of 
targeted therapy in the HRR of residence, such that the number of patients in each 
quintile was approximately equal.  We repeated the process for a second IV that 
estimated the annual rate of diffusion of chemotherapy treatment alone in each HRR.   
We constructed the instruments by calculating the rate of treatment by year within each 
HRR (chemotherapy or targeted therapy).   We tested the relationship between each IV 
on each treatment type (chemotherapy and targeted therapy) using the F-test to assess 
whether each IV explained a significant portion of the variation in treatment choice.  We 
also compared baseline characteristics by quintile of treatment diffusion for each IV 
separately to examine whether patients stratified according to rate of diffusion of each 
treatment type were similar in observed characteristics.   Tests for trend were 
conducted across quintiles of adoption rates to assess whether patients were 
comparable across levels of each IV.    
We adopted the two-stage least squares (2SLS) estimation approach for our IV-
based sensitivity analysis.   The outcomes considered for our sensitivity analysis were 
survival and cumulative costs at 1 year post diagnosis.  In each stage, we included 
baseline covariates to control for residual differences between treatment groups and 
HRR fixed effects to control for area-level confounders.  First, we estimated the 
probability of receiving targeted therapy as a function of baseline characteristics, HRR 
fixed effects and targeted therapy annual adoption rate at the HRR level.  We repeated 
the prediction model for receipt of chemotherapy alone.  In the second stage, we  
included both predicted probabilities of treatment (of targeted therapy and of 
chemotherapy), baseline characteristics and HRR fixed effects as covariates to predict 
	  
	  
17	  
1-year survival probabilities and cumulative costs by treatment group.   We compared 
the IV-based predicted outcomes to IPW analyses and non-weighted analyses using the 
same set of covariates. 
1.3  Results 
1.3.1 Baseline Characteristics 
A total of 10,285 patients met our eligibility criteria.  Within this cohort, 3,191 
(31%) received chemotherapy alone and for 1,834 (18%) patients treatment included a 
targeted therapy after diagnosis with Stage IV NSCLC.   Among the targeted therapy 
group, 591 (32%), 1,119 (61%) and 112 (6%) of patients received erlotinib, 
bevacizumab, or both drugs (with and without chemotherapy), respectively, during their 
course of disease.  Table 1.1 compares the patient, provider and area-level 
characteristics according to treatment group before and after weighting using the 
inverse probability of treatment (IPW, see a full list of covariates in Appendix).   As 
expected, in the unweighted comparisons there was evidence of treatment selection 
bias.  Patients who received any form of systemic therapy were more likely to be 
younger, married, have no comorbidities, and to be receiving care at a teaching 
hospital.  Treated patients had fewer proxy indicators of poor PS at baseline (requiring 
home health care and skilled nursing services, ADL aids or hospitalization) and lower  
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Table 1.1.  Baseline Characteristics. 
BSC	  	  	  	  	  	  Target	  	  	  	  Chemo	  	  
	  	  	  	  	  	  Proportion Standardized	  Difference	  
BSC	  	  	  	  	  	  Target	  	  	  	  Chemo	  	  
	  	  	  	  	  	  Proportion Standardized	  Difference	  
Characteristic	   Unweighted	   Inverse	  Probability	  of	  Treatment	  Weighted	  
Number	  of	  patients	   	  	  5,260	  	  	  	  1,834	  	   	  	  3,191	   5,260	  	  	  	  1,834	  	   	  	  3,191	  
Age	  at	  diagnosis	  
66-­‐69	   	  	  	  	  0.16	  	  	  	  	  	  0.25	  	   	  	  	  0.25	  	  	  	  	   	  	  	  	  0.22†	  	  	  	  0.23‡	  	  	  	  	  	  0.01¶ 	  0.19	  	  	  	  	  	  0.20	  	  	  	  	  	  	  0.22	  	   	  	  0.07†	  	  	  	  	  0.04‡	  	  	  	  	  	  0.03¶	  	  
70-­‐74	   	  	  	  	  0.22	  	  	  	  	  	  0.29	  	   	  	  	  0.30	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.20	  	   	  	  0.17	  	   	  	  0.03	   	  0.26	  	  	  	  	  	  0.27	  	  	  	  	  	  	  0.27	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.04	  	  	  	  	  	  	  0.03	  	   	  	  0.01	  
75-­‐79	   	  	  	  	  0.23	  	   	  	  0.25	  	   	  	  	  0.25	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.03	  	   	  	  0.05	  	  	  	  	  	  	  0.02	  	   	  0.24	  	  	  	  	  	  0.23	  	   	  	  	  	  0.24	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.01	  	   	  	  0.02	  	   	  	  0.03	  	  
80-­‐84	   	  	  	  	  0.21	  	  	  	  	  	  0.15	  	   	  	  0.16	  	   	  	  0.15	  	   	  	  0.18	  	  	  	  	  	  	  0.04	   	  0.19	  	  	   	  	  0.19	  	  	  	  	  	  	  0.17	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.05	  	   	  	  0.01	  	   	  	  0.03	  	  
85+	   	  	  	  	  0.18	  	  	  	  	  	  0.06	  	  	  	  	  	  	  0.05	  	   	  	  0.43	  	   	  	  0.38	  	   	  	  0.06	   	  0.13	  	  	  	  	  	  0.11	  	   	  	  	  	  0.10	  	   	  	  0.10	  	   	  	  0.04	  	   	  	  0.05	  	  
Female	  gender	   	  	  	  	  0.51	  	   	  	  	  0.54	  	  	  	  	  	  	  0.45	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.13	  	   	  	  0.06	  	   	  	  0.19	  	   	  0.50	  	  	  	  	  	  0.51	  	   	  	  0.49	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.04	  	   	  	  0.02	  	   	  	  0.05	  
Race/ethnicity	  
White	   	  	  	  0.79	  	  	  	  	  	  0.77	  	  	  	  	  	  	  0.83	  	   	  	  	  	  	  	  	  	  	  	  	  0.11	  	   	  	  0.05	  	   	  	  0.16	  	   	  0.81	  	  	  	  	  	  0.80	  	   	  	  	  	  0.81	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.01	  	   	  	  0.01	  	   	  	  0.02	  	  
Black	   	  	  	  0.10	  	  	  	  	  	  0.06	  	  	  	  	  	  	  0.08	  	   	  	  0.07	  	   	  	  0.15	  	   	  	  0.08	  	   	  0.08	  	   	  	  0.07	  	  	  	  	  	  	  0.09	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.02	  	   	  	  0.02	  	   	  	  0.04	  	  
Hispanic	   	  	  0.04	  	   	  	  0.05	  	  	  	  	  	  	  0.04	  	   	  	  0.03	  	  	  	  	  	  	  0.02	  	   	  	  0.05	  	   	  0.04	  	   	  	  0.05	  	  	  	  	  	  	  0.04	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.02	  	   	  	  0.03	  	   	  	  0.05	  
Other	   	  	  	  0.07	  	   	  	  0.13	  	  	  	  	  	  	  0.06	  	   	  	  0.07	  	   	  	  0.19	  	   	  	  0.25	   	  0.07	  	   	  	  0.07	  	  	  	  	  	  	  0.07	  	   	  	  	  0.02	  	   	  	  0.01	  	   	  	  0.03	  	  
Marital	  status	  
Single	   	  	  	  0.09	  	  	  	  	  	  0.09	  	  	  	  	  	  	  0.07	  	   	  	  0.06	  	   	  	  0.00	  	   	  	  0.07	  	   	  0.08	  	   	  	  0.08	  	   	  	  0.08	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.01	  	   	  	  0.01	  	   	  	  0.02	  	  
Married	   	  	  	  0.43	  	  	  	  	  	  0.58	  	   	  	  	  	  0.59	  	   	  	  0.31	  	   	  	  0.30	  	   	  	  0.01	  	   	  0.49	  	   	  	  0.49	  	   	  	  0.52	  	   	  	  0.06	  	   	  	  0.00	  	   	  	  0.06	  	  
Other	   	  	  	  0.48	  	   	  	  0.33	  	   	  	  	  	  0.35	  	   	  	  0.28	  	   	  	  0.31	  	   	  	  0.02	  	   	  0.43	  	   	  	  0.42	  	   	  	  	  	  0.40	  	   	  	  0.06	  	   	  	  0.01	  	  	  	  	  	  	  0.05	  	  
Comorbidity	  score**	  
0	   	  	  	  	  0.58	  	  	  	  	  	  0.67	  	  	  	  	  	  	  0.67	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.20	  	   	  	  0.20	  	   	  	  0.00	  	   	  	  0.61	  	  	  	  	  	  0.62	  	   	  	  	  	  0.63	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.04	  	   	  	  0.01	  	   	  	  0.03	  	  
1	   	  	  	  0.17	  	   	  	  	  0.16	  	  	  	  	  	  	  0.16	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.03	  	  	  	  	  	  	  0.03	  	   	  	  0.01	  	   	  	  0.17	  	   	  	  0.17	  	   	  	  0.17	  	   	  	  	  	  	  	  	  	  	  	  	  	  0.00	  	  	  	  	  	  0.01	  	   	  	  0.01	  	  
2	   	  	  	  0.09	  	   	  	  0.09	  	  	  	  	  	  	  0.07	  	   	  	  	  	  	  	  	  	  	  	  	  0.07	  	   	  	  0.02	  	   	  	  0.04	  	   	  	  0.09	  	  	   	  	  0.10	  	   	  	  0.08	  	  	  	   	  	  0.03	  	  	  	  	  	  0.04	  	   	  	  0.07	  	  
3+	   	  	  	  0.16	  	  	  	  	  	  0.08	  	  	  	  	  	  	  0.09	  	   	  	  0.20	  	  	  	  	  	  	  0.25	  	  	  	  	  	  0.05	  	   	  	  0.13	  	  	  	  	  	  0.12	  	   	  	  0.12	  	   	  	  0.04	  	   	  	  0.04	  	   	  	  0.00	  	  
COPD	  prior	  to	  
diagnosis	  
	  	  	  	  0.25	  	   	  	  0.21	  	   	  	  0.22	  	   	  	  0.07	  	   	  	  0.11	  	   	  	  0.04	   	  	  0.24	  	  	  	  	  	  0.24	  	  	  	  	  	  	  0.23	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.02	  	  	  	  	  	  0.01	  	  	  	  	  	  	  	  0.02	  	  
Brain	  metastases	   	  	  	  0.22	  	   	  	  0.12	  	  	  	  	  	  	  0.18	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  0.10	  	   	  	  0.28	  	   	  	  0.18	  	   	  	  0.19	  	   	  	  0.19	  	  	  	  	  	  	  0.18	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.02	  	   	  	  0.02	  	  	  	   	  	  0.01	  	  
Histology	  
Large	  cell	   	  	  	  	  0.05	  	  	  	  	  	  0.04	  	  	  	  	  	  	  0.05	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.02	  	  	  	  	  	  0.05	  	  	  	   	  	  0.07	  	   	  	  0.05	  	   	  	  0.04	  	   	  	  0.05	  	   	  	  0.01	  	   	  	  0.01	  	   	  	  0.02	  
Adenocarcinoma	   	  	  	  0.56	  	   	  	  	  0.64	  	  	  	  	  	  	  0.52	  	   	  	  0.07	  	   	  	  0.18	  	   	  	  0.25	  	   	  	  0.55	  	   	  	  0.56	  	   	  	  0.56	  	   	  	  0.01	  	   	  	  0.02	  	  	  	  	  	  	  	  0.01	  	  
BAC	   	  	  	  0.01	  	   	  	  0.03	  	  	  	  	  	  	  0.01	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.02	  	   	  	  0.12	  	   	  	  0.14	  	   	  	  0.02	  	   	  	  0.02	  	   	  	  0.02	  	   	  	  0.01	  	   	  	  0.02	  	   	  	  0.02	  
NOS	   	  	  	  0.38	  	   	  	  0.29	  	  	  	  	  	  	  0.42	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.07	  	   	  	  0.20	  	   	  	  0.27	  	   	  	  0.38	  	   	  	  0.38	  	   	  	  0.38	  	   	  	  0.01	  	   	  	  0.01	  	   	  	  0.00	  	  
Long-­‐term	  care	  	   	  	  	  	  0.15	  	   	  	  0.07	  	   	  	  0.08	  	   	  	  0.24	  	   	  	  0.27	  	   	  	  0.03	  	   	  	  	  0.12	  	  	  	  	  	  0.11	  	   	  	  	  0.11	  	   	  	  0.04	  	   	  	  0.03	  	   	  	  0.01	  	  
Skilled	  nursing	  
services	  	  
	  	  	  	  0.09	  	   	  	  0.02	  	   	  	  0.03	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.28	  	   	  	  0.29	  	  	  	  	  	  	  0.02	  	   	  	  0.06	  	   	  	  0.05	  	   	  	  	  0.04	  	   	  	  0.11	  	   	  	  0.04	  	   	  	  0.08	  	  
Home	  oxygen	   	  	  	  	  0.19	  	   	  	  0.13	  	   	  	  0.16	  	   	  	  0.08	  	   	  	  0.16	  	  	  	  	  	  	  0.08	  	   	  	  	  0.17	  	  	  	  	  	  0.16	  	   	  	  	  	  0.17	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.00	  	   	  	  0.03	  	   	  	  0.03	  	  
ADL	  aids	   	  	  	  	  0.12	  	   	  	  0.08	  	   	  	  0.06	  	   	  	  0.20	  	   	  	  0.14	  	   	  	  0.06	   	  	  	  0.10	  	   	  	  	  0.09	  	  	  	  	  	  	  0.09	  	   	  	  0.05	  	   	  	  0.05	  	   	  	  0.00	  	  
Medicaid	  enrollment	   	  	  	  	  0.22	  	   	  	  0.21	  	   	  	  0.12	  	   	  	  0.27	  	   	  	  0.01	  	   	  	  0.25	   	  	  	  0.19	  	  	  	  	  	  0.18	  	   	  	  	  0.16	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.07	  	   	  	  0.01	  	   	  	  0.06	  	  
Urban	  residence	   	  	  	  	  0.90	  	   	  	  0.91	  	   	  	  0.90	  	   	  	  0.02	  	   	  	  0.02	  	   	  	  0.04	  	   	  	  0.90	  	  	   	  	  0.90	  	  	  	  	  	  	  0.90	  	   	  	  0.00	  	   	  	  0.01	  	   	  	  0.00	  	  
Teaching	  hospital	   	  	  	  	  0.00	  	   	  	  0.17	  	   	  	  0.26	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.84	  	   	  	  0.64	  	   	  	  0.23	  	   	  	  	  0.00	  	   	  	  0.12	  	  	  	  	  	  	  0.12	  	   	  	  0.52	  	   	  	  0.51	  	   	  	  0.01	  	  
College	  education	  ***	  	  
1(low)	   	  	  	  	  0.21	  	   	  	  0.16	  	   	  	  0.19	  	   	  	  0.04	  	   	  	  0.13	  	   	  	  0.09	   	  	  0.20	  	   	  	  0.20	  	   	  	  0.20	  	   	  	  	  	  	  	  0.00	  	   	  	  0.00	  	   	  	  0.00	  
2	   	  	  	  	  0.20	  	  	  	  	  	  0.20	  	   	  	  0.19	  	   	  	  0.03	  	   	  	  0.01	  	   	  	  0.02	  	   	  	  0.21	  	   	  	  0.19	  	   	  	  0.20	  	   	  	  0.02	  	   	  	  0.04	  	   	  	  0.02	  	  
3	   	  	  	  	  0.19	  	   	  	  0.19	  	   	  	  0.21	  	   	  	  0.04	  	  	  	  	  	  	  0.01	  	   	  	  0.05	  	   	  	  0.20	  	   	  	  0.20	  	   	  	  0.20	  	   	  	  0.01	  	   	  	  0.00	  	   	  	  0.01	  	  
4	   	  	  	  	  0.21	  	   	  	  0.19	  	   	  	  0.21	  	   	  	  0.01	  	   	  	  0.02	  	   	  	  0.04	  	   	  	  0.20	  	   	  	  0.21	  	   	  	  0.21	  	   	  	  0.00	  	   	  	  0.01	  	   	  	  0.00	  	  
5	  (high)	   	  	  	  	  0.19	  	   	  	  0.26	  	   	  	  0.19	  	   	  	  	  0.01	  	  	  	  	  	  	  0.16	  	   	  	  0.15	  	   	  	  0.19	  	   	  	  0.20	  	   	  	  0.20	  	   	  	  0.01	  	   	  	  0.03	  	   	  	  0.02	  	  
Income***	  
1	  (low)	   	  	  	  	  0.21	  	   	  	  0.16	  	   	  	  0.19	  	   	  	  0.06	  	   	  	  0.14	  	   	  	  0.07	   	  	  0.20	  	   	  	  0.19	  	   	  	  0.20	  	   	  	  0.01	  	   	  	  	  0.02	  	   	  	  0.01	  	  
2	   	  	  	  	  0.20	  	   	  	  0.19	  	   	  	  0.19	  	   	  	  0.03	  	   	  	  0.04	  	   	  	  0.01	  	   	  	  0.20	  	   	  	  0.20	  	   	  	  0.20	  	   	  	  0.02	  	   	  	  0.00	  	   	  	  0.01	  	  
3	   	  	  	  	  0.2	  0	  	  	  	  	  0.20	  	  	  	  	  	  	  0.20	  	   	  	  0.01	  	   	  	  0.01	  	   	  	  0.00	  	   	  	  	  0.20	  	   	  	  0.20	  	   	  	  0.20	  	   	  	  0.00	  	   	  	  0.00	  	   	  	  0.00	  
4	   	  	  	  	  0.20	  	   	  	  0.20	  	   	  	  0.20	  	  	  	   	  	  0.00	  	  	  	  	  	  	  0.00	  	   	  	  0.00	   	  	  0.20	  	   	  	  0.20	  	   	  	  0.20	  	   	  	  0.01	  	   	  	  0.01	  	   	  	  0.00	  	  
5	  (high)	   	  	  	  	  0.18	  	   	  	  0.25	  	   	  	  0.21	  	   	  	  0.08	  	  	  	  	  	  	  0.16	  	   	  	  0.08	  	   	  	  0.19	  	   	  	  0.20	  	   	  	  0.21	  	   	  	  0.04	  	   	  	  0.03	  	   	  	  0.01	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Table 1.1. (Continued) 
*Other	  covariates	  included	  in	  PS	  estimation:	  Alcohol	  abuse,	  Cardiac	  arrhythmias,	  CHF,	  Chronic
pulmonary	  disease,	  Coagulopathy,	  Complicated	  diabetes,	  Deficiency	  anemias,	  Dementia,	  Fluid	  
and	  electrolyte	  disorder,	  HIV/AIDS,	  Hemiplegia,	  Hypertension,	  Liver	  disease,	  PVD,	  Psychosis,	  
Pulmonary	  circulation	  disorder,	  Renal	  failure,	  Weight	  loss,	  hospital	  days	  for	  COPD	  prior	  to	  
cancer	  diagnosis,	  census	  tract	  level	  hospital	  bed	  and	  physician	  density,	  managed	  care	  
penetration,	  proportion	  foreign	  born,	  hospital	  length	  of	  stay	  within	  a	  year	  prior	  to	  cancer	  
diagnosis,	  hospital	  referral	  region	  not	  shown	  (see	  Appendix)	  	  **determined	  using	  Charlson	  and	  
Elixhauser	  combined	  score	  †chemotherapy vs. BSC ‡targeted therapy vs. BSC ¶targeted 
therapy vs. chemotherapy ***	  census	  tract	  quintile	  
medical costs prior to diagnosis.   Patients treated with targeted therapy compared to 
chemotherapy alone were more likely to be female, non-Hispanic, non-white, or non-
black, have a histopathologic diagnosis of adenocarcinoma and Medicaid co-insurance, 
live in areas with high managed care penetration, and areas with a highly educated and 
foreign born population.  Compared to the chemotherapy alone treatment group, those 
treated with targeted therapy were less likely to have brain metastases or to be treated 
at a teaching hospital.  In the IPW analyses, the balance in the baseline characteristics 
across the treatment groups improved considerably.  All standardized differences were 
notably smaller than 10% with the exception of a higher proportion of systemic therapy 
patients who were managed at a teaching hospital compared to the BSC group. 
BSC	  	  	  	  	  	  Target	  	  	  	  Chemo	  	  
	  	  	  	  	  	  Proportion Standardized	  Difference	  
BSC	  	  	  	  	  	  Target	  	  	  	  Chemo	  	  
	  	  	  	  	  	  Proportion Standardized	  Difference	  
Characteristic	   Unweighted	   Inverse	  Probability	  of	  Treatment	  Weighted	  
Prior	  year	  costs	  
(quintile)	  	  
1	  (low)	   	  	  	  	  0.21	  	   	  	  0.17	  	   	  	  0.20	  	   	  	  0.03	  	   	  	  0.11	  	   	  	  0.08	  	   	  	  0.20	  	   	  	  0.19	  	  	  	  	  	  	  0.20	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.00	  	   	  	  0.03	  	   	  	  0.02	  	  
2	   	  	  	  	  0.18	  	   	  	  0.22	  	   	  	  0.22	  	   	  	  0.09	  	   	  	  0.10	  	   	  	  0.01	  	   	  	  0.19	  	   	  	  0.20	  	   	  	  0.20	  	   	  	  0.02	  	   	  	  0.02	  	   	  	  0.00	  	  
3	   	  	  	  	  0.18	  	   	  	  0.23	  	   	  	  0.21	  	   	  	  	  	  	  0.07	  	   	  	  0.11	  	  	  	  	  	  	  0.04	  	   	  	  0.20	  	   	  	  0.21	  	   	  	  	  	  0.20	  	   	  	  0.01	  	   	  	  0.02	  	   	  	  0.01	  	  
4	   	  	  	  	  0.18	  	   	  	  0.23	  	   	  	  0.21	  	   	  	  0.07	  	   	  	  0.13	  	   	  	  0.06	  	   	  	  0.20	  	   	  	  0.19	  	   	  	  0.20	  	   	  	  0.02	  	   	  	  0.03	  	   	  	  0.04	  	  
5	  (high)	   	  	  	  	  0.24	  	   	  	  0.15	  	   	  	  0.16	  	   	  	  0.20	  	   	  	  0.24	  	  	  	  	  	  	  0.04	   	  	  0.21	  	   	  	  0.21	  	   	  	  0.19	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.04	  	  	  	  	  	  	  0.01	  	   	  	  0.06	  	  
Year	  of	  diagnosis	  
2007	   	  	  	  	  0.34	  	   	  	  0.34	  	   	  	  0.34	  	   	  	  0.01	  	   	  	  0.00	  	   	  	  0.01	  	   	  	  0.34	  	   	  	  0.33	  	  	  	  	  	  	  0.34	  	   	  	  0.01	  	   	  	  0.02	  	   	  	  0.01	  
2008	   	  	  	  	  0.34	  	   	  	  0.32	  	   	  	  0.34	  	   	  	  0.01	  	   	  	  0.05	  	   	  	  0.05	  	   	  	  0.34	  	   	  	  0.34	  	   	  	  0.34	  	   	  	  0.01	  	   	  	  0.01	  	   	  	  0.00	  
2009	   	  	  	  	  0.32	  	   	  	  0.34	  	   	  	  0.32	  	   	  	  0.00	  	   	  	  0.04	  	  	  	  	  	  	  0.04	  	   	  	  0.32	  	   	  	  0.33	  	   	  	  0.32	  	   	  	  0.00	  	  	  	  	  	  	  0.02	  	   	  	  0.01	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1.3.2  Life Expectancy 
Patients who were ever exposed to cancer-directed treatment during their course 
of disease with Stage IV lung cancer had a longer survival compared to those managed 
with BSC.  Based on undiscounted survival time and doubly robust, IPW Cox PH 
models, the median overall survival estimates were 2.4 (IQR, 1.3-5.2), 6.5 (IQR, 3.3-
13.1), and 9.8 (IQR, 4.7-17.2) months in the BSC, chemotherapy and targeted therapy 
groups, respectively.   Surprisingly, our subgroup analysis based on first-line therapy 
exposure, revealed that the adjusted median survival for patients selected for first line 
erlotinib therapy in routine care was only marginally longer compared to a 
counterfactual group of patients managed with BSC, 4.7 (IQR, 2.7-11.5) months vs. 2.6 
(IQR, 1.3-5.5) months.   A much longer median adjusted OS was observed for those 
treated with first line doublet chemotherapy, 8.1 months (IQR, 4.1-15.5), and for patients 
who initiated combination therapy with bevacizumab, 10.5 months (IQR, 5.6-18.3). 
Discounted mean life expectancy and lifetime costs adjusted for inflation (2013 $) 
are shown in Tables 1.2 and 1.3 by treatment ‘ever’ category and for first-line treatment 
subgroups, respectively.  These lifetime estimates are based on IPW, doubly-robust 
analyses and projections beyond last censored observation.   The largest discounted 
mean life expectancy improvement, of 5.4 months, was seen in patients ever treated 
with chemotherapy alone relative to those managed with BSC (Table 1.2).   Patients 
who received targeted therapy at some point, lived on average 2.4 months longer 
compared to cases treated with chemotherapy alone (Table 1.2).  Based on first-line 
therapy subgroup analyses (Table 1.3), the mean life expectancy increased by only 1.2 
months for treatments that combined bevacizumab with a chemotherapy doublet vs. 
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chemotherapy alone.  The mean survival associated with first line erlotinib therapy was 
substantially shorter compared to treatment with a chemotherapy doublet, 8.5 vs. 12.2 
months. 
Table 1.2.  Cost Effectiveness Analysis Results by Treatment Category ‘Ever’.  
Treatment*	   Mean	  
Lifetime	  
Cost†
Cost	  
Difference	  
Mean	  Life	  
Expectancy†	  
(months)	  
Mean	  Life	  
Expectancy	  
(years)	  
Change	  in	  
Life	  
Expectancy	  
(years)	  
ICER‡	  
($/LY)	  
BSC¶ $45,556	   5.28	   0.44	  
Any	  Chemotherapy	   $86,039	   $40,483	   10.66	   0.89	   0.45	   90,297	  
Targeted	   $125,119	   $39,080	   13.02	   1.16	   0.20	   198,712	  
Table 1.3. Cost Effectiveness Analysis Results by First-Line Therapy.
Treatment**	   Mean	  
Lifetime	  
Cost†
Cost	  
Difference	  
Mean	  Life	  
Expectancy†	  
(months)	  
Mean	  Life	  
Expectancy	  
(years)	  
Change	  in	  
Life	  
Expectancy	  
(years)	  
ICER	  
($/LY)	  
BSC¶ $47,902	   5.17	   0.43	  
Erlotinib	   $83,732	   dominated	   8.51	   0.71	   dominated	   dominated	  
Doublet	  
Chemotherapy	   $95,154	   $47,252	   12.21	   1.02	   0.59	   80,543	  
Bevacizumab	   $149,987	   $54,833	   13.43	   1.12	   0.10	   548,330	  
*patients	  grouped	  into	  treatment	  categories	  based	  on	  receipt	  of	  treatment	  anytime	  after	  diagnosis;	  based	  on	  projected	  costs	  and	  survival
beyond	  last	  observed	  data	  (extended	  means)	  
†	  based	  on	  doubly	  robust	  estimators	  (inverse	  probability	  weighting	  by	  propensity	  score	  and	  multivariate	  outcome	  regression	  models);	  models	  
were	  adjusted	  for	  age,	  race,	  gender,	  marital	  status,	  comorbidity	  score,	  individual	  comorbidities,	  histology,	  brain	  metastases,	  enrollment	  in	  
Medicaid,	  urban	  residence,	  hospital	  teaching	  status,	  pre-­‐diagnosis	  costs,	  indicators	  of	  functional	  status	  prior	  to	  diagnosis	  (skilled	  nursing,	  long-­‐
term	  care,	  hospital	  stays,	  use	  of	  home	  oxygen,	  ADL	  aids),	  census	  level	  college	  education,	  income,	  physician	  density,	  hospital	  bed	  density,	  
managed	  care	  penetration,	  proxy	  indicator	  for	  acculturation	  (proportion	  foreign	  born),	  year	  of	  diagnosis,	  and	  hospital	  referral	  region	  
‡ICER=incremental	  cost	  effectiveness	  ratio,	  ratio	  of	  difference	  in	  mean	  lifetime	  costs	  (2013	  $)	  	  to	  mean	  life	  years	  ;	  after	  1	  year,	  costs	  and	  
survival	  length	  discounted	  by	  3%	  per	  annum	  
¶BSC=best	  supportive	  care	  
**patients	  grouped	  into	  treatment	  categories	  based	  on	  first-­‐line	  therapy	  initiation	  within	  120	  days	  from	  diagnosis	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1.3.3  Costs 
On average, the discounted cost of medical management with BSC over a 
lifetime was $45,600 (2013 US$).  The corresponding lifetime cost estimates for the 
chemotherapy and targeted therapy groups were $86,000 and $125,100, respectively, 
or approximately $40,000 more for each technological advance (Table 1.2).    
Patients who initiated therapy with a bevacizumab-based combination treatment, 
had the highest lifetime costs of around $150,000 (Table 1.3).  Costs for those who 
were treated with first-line chemotherapy were approximately $55,000 lower over a 
lifetime compared to the first-line bevacizumab group.   
We also decomposed the cumulative medical expenditures by service type and 
into monthly spending by phase of care (Table 1.4 and 1.5).   First, we carried out a 
comparison of mean IPW monthly costs by phase of care between the BSC patients 
and each of the treatment groups prior to initiation of therapy to examine whether 
residual unobserved confounders may explain the differences in cumulative and 
monthly costs.  These analyses revealed no significant differences in monthly costs 
(data not shown), bolstering the case that group differences in cumulative and monthly 
costs arose from survival differences and treatment-related management.    
The decomposed estimates revealed that systemic therapy costs account for the 
largest proportion of medical care costs.  In the targeted therapy group, a quarter of the 
overall spending, or $32,300, was attributable to costs related to targeted treatments, 
and another 20% of total costs, approximately $25,000, was spent on chemotherapy 
(drug costs and administration costs).   Similarly, in the chemotherapy treatment only 
group, drug related costs accounted for a substantial proportion (22.0%) of the total 
expenditures (Table 1.4).   
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Table 1.4.   Costs by Category of Spending and Treatment (2013 $). 
Treatment*	   Durable	  MedicalEquipment	  
Home	  Health	  
Agency	   Hospice	   Inpatient	  Hospital	   Physician	   Outpatient	   Chemotherapy	   Target	  Therapy	   Total	  Cost	  
BSC	   $588	   1.3%†	   $946	   2.1%	   $4,485	   9.8%	   $25,654	   56.3%	   $9,561	   21.0%	   $4,322	   9.5%	   $0	   0.0%	   $0	   0.0%	   $45,556	  
Chemo	   $1,215	   1.4%	   $2,349	   2.7%	   $3,900	   4.5%	   $32,137	   37.4%	   $18,152	   21.1%	   $9,358	   10.9%	   $18,928	   22.0%	   $0	   0.0%	   $86,039	  
Targeted	   $868	   0.7%	   $2,322	   1.9%	   $3,815	   3.0%	   $31,622	   25.3%	   $19,490	   15.6%	   $9,797	   7.8%	   $24,912	   19.9%	   $32,293	   25.8%	   $125,119	  
* using Kaplan-Meier Sample Average (KMSA) cost estimator based on doubly robust, inverse probability  of treatment
weighted (IPW) monthly costs and survival probabilities ;  propensity of receiving a treatment was estimated using 
multinomial logistic regression model with the following covariates: age, race, gender, marital status, comorbidity score, 
individual comorbidities, histology, brain metastases, enrollment in Medicaid, urban residence, hospital teaching status, 
pre-diagnosis costs, indicators of functional status prior to diagnosis (skilled nursing, long-term care, hospital stays, use of 
home oxygen, ADL aids), census level college education, income, physician density, hospital bed density, managed care 
penetration, proxy indicator for acculturation (proportion foreign born), year of diagnosis, and hospital referral region; after 
1 year, costs discounted by 3% per annum 
†percent of total cost 
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The terminal phase was the most resource intensive period.  Although the 
monthly terminal costs were comparable across all treatment groups, it is noteworth y 
that the pattern of spending did differ across the groups (Table 1.5).  For example, 
patients in the BSC group had significantly higher inpatient hospital monthly costs 
compared to patients treated with systemic therapy.  Interestingly, a large amount of
spending in the terminal phase continued to be allocated towards drug therapy for 
patients who received any form of systemic therapy (Table 1.5).  For example, in the 
targeted therapy group, 20% of terminal phase costs were attributable to drug therap y,
and a mean of $1,492 per month was spent on targeted therapy alone.   
The initial phase of treatment was also associated with high mean monthly tot al 
costs (Table 1.5). Almost 20% and 40% of the costs in the initial phase were compri sed
of drug therapy spending in the chemotherapy and targeted therapy groups, 
respectively.    The continuing phase was the least costly (total monthly cost range: 
$3,392 - $7,573), but net of drug costs, the monthly costs in this phase did not differ by
treatment group. 
1.3.4  Cost-Effectiveness Analysis 
For strategies based on treatment exposure ever, the incremental cost 
effectiveness ratios (ICERs) using a lifetime horizon were $90,300 per year of life an d
$198,700 per life-year for chemotherapy vs. BSC and targeted therapy vs. 
chemotherapy respectively (Table 1.2). 
In our subgroup analysis which compared groups according to first-line therapy, y,
tedthe erlotinib strategy was eliminated by extended dominance since the ICER 
associated with this treatment was higher compared to the ICER for first-line 
chemotherapy.
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Table 1.5.  Monthly Costs by Phase of Care and Treatment (2013 $). 
Treatmen
t*	  
Phase	   Total	  Costs	   Costs	  without	  
Drug	  Therapy	  
Inpatient	  
Hospital	  Costs	  
Outpatient	  
Costs	  
Physician	  	  
Costs	  
Hospice	  
Costs	  
Home	  
Health	  
Care	  Costs	  
Durable	  
Medical	  
Equipment	  
Costs	  
Chemother
apy	  Costs	  
Targeted	  
Therapy	  Costs	  
Mean	  (95%	  CI)	  
2013	  US	  $	  
Targeted	  
Therapy	  
Initial	  
Continuing	  
Terminal	  
11,874	  	  
(11,460-­‐12,288)	  
	  	  7,573	  	  
	  (7,245-­‐7,901)	  
12,015	  	  
(11,400-­‐12,630)	  
	  	  7,247	  	  
(6,877-­‐7,617)	  
	  	  2,927	  	  
	  (2,750-­‐3,105)	  
	  	  9,619	  	  
(9,041-­‐10,198)	  
3,359	  
(3,066-­‐3,651)	  
907	  
(804-­‐1,011)	  
5,575	  
(5,081-­‐6,070)	  
1,323	  
(1,235-­‐1,411)	  
583	  
(535-­‐631)	  
761	  
(573-­‐948)	  
2,308	  
(2,194-­‐2,422)	  
1,080	  
(1,020-­‐1,141)	  
1,717	  
(1,615-­‐1,819)	  
14	  
(1-­‐26)	  
125	  
(78-­‐171)	  
1,065	  
(958-­‐1,171)	  
147	  
(122-­‐171)	  
149	  
(123-­‐175)	  
389	  
(334-­‐444)	  
97	  
(78-­‐116)	  
79	  
(63-­‐96)	  
113	  
(99-­‐127)	  
1,902	  	  
(1,724-­‐2,080)	  
2,058	  	  
(1,867-­‐2,249)	  
	  	  	  903	  	  
(797-­‐1,009)	  
2,726	  	  
(2,542-­‐2,909)	  
2,587	  	  
(2,396-­‐2,779)	  
1,492	  	  
(1,362-­‐1,623)	  
Chemothe
rapy	  
Initial	  
Continuing	  
Terminal	  
10,168	  	  
	  (9,847-­‐10,490)	  
	  	  5,139	  	  
	  (4,897-­‐5,381)	  
11,850	  	  
(11,444-­‐12,257)	  
	  	  8,329	  	  
	  (8,009-­‐8,650)	  
	  	  3,190	  	  
	  (2,992-­‐3,389)	  
10,685	  	  
(10,283-­‐11,088)	  
3,820	  
(3,553-­‐4,087)	  
1,169	  
(1,032-­‐1,305)	  
6,351	  
(5,993-­‐6,708)	  
1,555	  
(1,481-­‐1,629)	  
594	  
(554-­‐634)	  
785	  
(736-­‐835)	  
2,717	  
(2,622-­‐2,811)	  
1,084	  
(1,014-­‐1,154)	  
2,046	  
(1,958-­‐2,133)	  
11	  
(5-­‐17)	  
122	  
(89-­‐154)	  
1,034	  
(961-­‐1,107)	  
143	  
(120-­‐166)	  
143	  
(123-­‐163)	  
360	  
(329-­‐390)	  
84	  
(76-­‐93)	  
82	  
(71-­‐94)	  
110	  
(101-­‐119)	  
1,839	  
	  (1,745-­‐1,933)	  
1,949	  
	  (1,812-­‐2,086)	  
1,165	  	  
(1,090-­‐1,240)	  
n/a	  
BSC	  
Initial	  
Continuing	  
Terminal	  
	  	  8,493	  	  
	  (8,074-­‐8,913)	  
	  	  3,392	  	  
(3,106-­‐3,678)	  
12,711	  	  
	  (12,351-­‐
13,071)	  
	  	  8,493	  	  
(8,074-­‐8,913)	  
	  	  3,392	  	  
	  (3,106-­‐3,678)	  
12,711	  
	  (12,351-­‐
13,071)	  
4,759	  
(4,412-­‐5,106)	  
1,027	  
(863-­‐1,191)	  
8,203	  
(7,876-­‐8,531)	  
1,192	  
(1,040-­‐1,345)	  
636	  
(542-­‐730)	  
633	  
(597-­‐668)	  
2,079	  
(1,984-­‐2,174)	  
1,071	  
(912-­‐1,230)	  
2,049	  
(1,984-­‐2,115)	  
222	  
(188-­‐256)	  
420	  
(334-­‐505)	  
1,469	  
(1,409-­‐
1,529)	  
158	  
(138-­‐178)	  
123	  
(101-­‐144)	  
261	  
(243-­‐280)	  
83	  
(73-­‐93)	  
81	  
(67-­‐94)	  
90	  
(83-­‐97)	  
n/a	   n/a	  
*estimates based on inverse probability  of treatment weighted (IPW) monthly costs;  propensity of receiving a treatment
was estimated using multinomial logistic regression model with the following covariates: age, race, gender, marital status, 
comorbidity score, individual comorbidities, histology, brain metastases, enrollment in Medicaid, urban residence, hospital 
teaching status, pre-diagnosis costs, indicators of functional status prior to diagnosis (skilled nursing, long-term care, 
hospital stays, use of home oxygen, ADL aids), census level college education, income, physician density, hospital bed 
density, managed care penetration, proxy indicator for acculturation (proportion foreign born), year of diagnosis, and 
hospital referral region
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  The first-line chemotherapy strategy compared to BSC yielded an ICER of$80,500 
per additional life year (Table 1.3).  Relative to first-line chemotherapy, the addition 
of bevacizumab to first-line therapy resulted in a cost of almost $550,000 pe life year 
gained (Table 1.3). 
1.3.5  Sensitivity Analyses 
We conducted several sensitivity analyses to test the effects of modeling 
assumptions and potential omitted variable bias on our results.   In table 1.6, we present
the results of several modeling approaches that were done using restricted mean 
outcomes (without extrapolation beyond observed period).   Not accounting for selection
bias based on observed confounders resulted in a more favorable ICER for 
chemotherapy, at around $85,000 per year of life, and for targeted therapy, at $160,000
per year of life, compared to the next best strategy.  Our base case analysis, IPW 
multivariate models adjusted for residual confounding including fixed HRR effects, 
produced an ICER for targeted therapy in mid-range of other modeling approaches, 
$91,700 and $184,400 per life year for chemotherapy and targeted therapy, 
respectively.  Without the doubly-robust estimation, IPW weighted analyses with HRR
fixed effects yielded slightly lower ICERs and those without HRR fixed effects produced
a higher ICER for targeted therapy.  These results suggest some residual confounding
by baseline characteristics and HRR residence, albeit to a small extent, compared to
analyses that were based on IPW estimation alone.    
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Table 1.6.  Sensitivity Analyses. 
Models	   Treatment	   Mean	  
Cost	  
Cost	  
Difference	  
Mean	  Life	  
Expectancy	  
(months)	  
Mean	  Life	  
Expectancy	  
(years)	  
Change	  in	  
Life	  
Expectancy	  
(years)	  
ICER†	  
($/LY	  
gained)	  
Unadjusted	  
BSC‡
Chemotherapy	  
Target	  Therapy	  
$45,391	  
$89,456	  
$142,233	  
$44,065	  
$52,777	  
5.10	  
11.35	  
15.32	  
0.43	  
0.95	  
1.28	  
0.52	  
0.33	  
84,740	  
159,930	  
Doubly	  
robust**,¶
BSC	  
Chemotherapy	  
Target	  Therapy	  
$45,410	  
$85,355	  
$124,377	  
$39,945	  
$39,022	  
5.24	  
10.47	  
13.01	  
0.44	  
0.87	  
1.08	  
0.44	  
0.21	  
91,652	  
184,356	  
IPW	  with	  
HRR	  fixed	  
effects	  **,††
BSC	  
Chemotherapy	  
Target	  Therapy	  
	  	  $45,865	  
$85,328	  
$126,445	  
$39,463	  
$41,117	  
5.40	  
10.95	  
13.77	  
0.45	  
0.91	  
1.15	  
0.46	  
0.24	  
85,789	  
171,321	  
IPW	  without	  
HRR	  fixed	  
effects ¶¶,‡‡
BSC	  
Chemotherapy	  
Target	  Therapy	  
$46,080	  
$87,507	  
$130,735	  
$41,427	  
$43,228	  
5.44	  
11.21	  
13.79	  
0.45	  
0.93	  
1.15	  
0.48	  
0.22	  
86,306	  
196,491	  
*based	  on	  observed	  data	  (restricted	  means)
†	  ICER=incremental	  cost	  effectiveness	  ratio,	  ratio	  of	  difference	  in	  mean	  lifetime	  costs	  (2013	  $)	  to	  mean	  life	  years	  ;	  	  
after	  1	  year,	  costs	  and	  survival	  length	  discounted	  by	  3%	  per	  annum	  
‡BSC=best	  supportive	  care	  
¶based	  on	  doubly	  robust	  estimators	  (inverse	  probability	  weighting	  by	  propensity	  score	  and	  multivariate	  outcome	  regression	  models);	  	  
models	  were	  adjusted	  for	  age,	  race,	  gender,	  marital	  status,	  comorbidity	  score,	  individual	  comorbidities,	  histology,	  brain	  metastases,	  enrollment	  
in	  Medicaid,	  urban	  residence,	  hospital	  teaching	  status,	  pre-­‐diagnosis	  costs,	  indicators	  of	  functional	  status	  prior	  to	  diagnosis	  (skilled	  nursing,	  
long-­‐term	  care,	  hospital	  stays,	  use	  of	  home	  oxygen,	  ADL	  aids),	  census	  level	  college	  education,	  income,	  physician	  density,	  hospital	  bed	  density,	  
managed	  care	  penetration,	  proxy	  indicator	  for	  acculturation	  (proportion	  foreign	  born),	  year	  of	  diagnosis,	  and	  hospital	  referral	  region	  fixed	  
effects	  
**propensity	  of	  receiving	  a	  treatment	  was	  estimated	  using	  multinomial	  logistic	  regression	  model	  with	  the	  following	  covariates:	  age,	  race,	  
gender,	  marital	  status,	  comorbidity	  score,	  individual	  comorbidities,	  histology,	  brain	  metastases,	  enrollment	  in	  Medicaid,	  urban	  residence,	  
hospital	  teaching	  status,	  pre-­‐diagnosis	  costs,	  indicators	  of	  functional	  status	  prior	  to	  diagnosis	  (skilled	  nursing,	  long-­‐term	  care,	  hospital	  stays,	  use	  
of	  home	  oxygen,	  ADL	  aids),	  census	  level	  college	  education,	  income,	  physician	  density,	  hospital	  bed	  density,	  managed	  care	  penetration,	  proxy	  
indicator	  for	  acculturation	  (proportion	  foreign	  born),	  year	  of	  diagnosis,	  and	  hospital	  referral	  region	  
††	  Kaplan-­‐Meier	  Sample	  Average	  (KMSA)	  included	  estimates	  from	  models	  with	  inverse	  probability	  of	  treatment	  weights	  (IPW)	  and	  HRR	  fixed	  
effects	  
‡‡	  Kaplan-­‐Meier	  Sample	  Average	  (KMSA)	  included	  estimates	  from	  models	  with	  inverse	  probability	  of	  treatment	  weights	  (IPW)	  	  
¶¶propensity	  of	  receiving	  a	  treatment	  was	  estimated	  using	  multinomial	  logistic	  regression	  model	  with	  the	  following	  covariates:	  age,	  race,	  
gender,	  marital	  status,	  comorbidity	  score,	  individual	  comorbidities,	  histology,	  brain	  metastases,	  enrollment	  in	  Medicaid,	  urban	  residence,	  
hospital	  teaching	  status,	  pre-­‐diagnosis	  costs,indicators	  of	  functional	  status	  prior	  to	  diagnosis	  (skilled	  nursing,	  long-­‐term	  care,	  hospital	  stays,	  use	  
of	  home	  oxygen,	  ADL	  aids),	  census	  level	  college	  education,	  income,	  physician	  density,	  hospital	  bed	  density,	  managed	  care	  penetration,	  proxy	  
indicator	  for	  acculturation	  (proportion	  foreign	  born),	  and	  year	  of	  diagnosis	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1.3.6  Instrumental Variable Analysis 
The instruments using HRR-by-year rates of the adoption of targeted therapy and 
chemotherapy significantly predicted the likelihood of lung cancer treatment choices (F 
= 147 and 125, p-value <.001, respectively for targeted therapy and chemotherapy).    
The likelihood of receiving treatment was significantly associated with the quintile of the 
instruments - chemotherapy receipt increased from 17.8% to 45.0% and targeted 
therapy ranged from 6.3% to 30.5% from the lowest quintile to the highest quintile of the 
instruments.  Patient characteristics according to the lowest and highest quintile of each 
instrument were reasonably balanced across the quintiles of the instruments (see 
Appendix).  Residual differences were controlled for in the doubly-robust estimation.    
The instrumental variable analyses indicated that the incremental 6-month and 12-
month differences between strategies in overall survival and cumulative costs were not 
significantly different from differences estimated by the doubly-robust IPW approach.   
1.4  Discussion 
We performed a cost-effectiveness analysis of targeted therapies outside the 
clinical trial setting in a population-based study of elderly patients with Stage IV NSCLC. 
Our results indicate that targeted therapy given in routine care generates a modest 
survival benefit compared to chemotherapy alone.  Unlike most cost-effectiveness 
analyses, which are based on decision analytic models with efficacy inputs from 
selected clinical trial participants, we based our study on the real-world setting to reflect 
effectiveness and expenditure outcomes using contemporary practice patterns.  Our 
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results suggest that the incremental cost-effectiveness ratio for targeted therapy of 
$198,700 per additional life year exceeds the WHO acceptable willingness to pay 
threshold for a cost-effective intervention of $150,000 per life year.[45]  In a subgroup 
analysis, we found that initiation of bevacizumab in combination with chemotherapy 
yielded an ICER of almost $550,000 per life-year.  First-line erlotinib therapy was a 
dominated strategy since it resulted in an ICER that was higher than that for first-line 
doublet chemotherapy, yet its effectiveness in terms of life expectancy was lower, 8.5 
months vs. 12.2 months, respectively.    
Our results for first-line bevacizumab-based therapy are consistent in value with 
an economic analysis which used efficacy outcomes from the landmark trial (ECOG 
4599) comparing carboplatin and paclitaxel with and without bevacizumab that yielded 
an ICER of $309,000 per life year from the US payer perspective.[18, 46]  Both, our 
observational study and the trial-based cost-effectiveness analysis suggest that 
bevacizumab treatment is associated with a low economic value.  The survival 
outcomes observed in our study among patients who were treated with bevacizumab in 
the first line setting were comparable to those reported by Zhu, et al.[14]   In that 
observational study of patients aged 65 years or older, the median OS for bevacizumab 
in combination with carboplatin and paclitaxel was 9.7 months and the 1-year survival 
probability was 39.6%, outcomes that were not significantly different from carboplatin 
and paclitaxel combination therapy alone.  More careful selection of patients in a trial 
setting yielded results for overall survival that ranged from non-significant to a 2-month 
significant benefit in the ECOG 4599 trial for bevacizumab combination therapy 
compared to chemotherapy alone.[11, 47, 48]  In contrast to the known predictive 
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biomarkers which correlate with response to erlotinib, factors predictive of response or 
toxicity with bevacizumab in non-squamous cell tumors are yet to be elucidated.[49]  
Future research should focus on identifying predictive markers to guide bevacizumab 
therapy towards subgroups of patients who are more likely to benefit from addition of 
bevacizumab to first-line chemotherapy. 
Our finding of a surprisingly low adjusted median OS of 4.7 months for patients 
selected for first line erlotinib therapy in routine care compared to a counterfactual group 
of patients treated with first line doublet chemotherapy of 8.1 months warrants a closer 
examination of treatment prescribing patterns.  In a companion observational analysis of 
elderly lung cancer patients, we found that only 5.2% of Stage IV non-squamous 
NSCLC patients had a claim for a molecular test prior to initiation of first-line therapy.(ref 
3rd paper)   This finding is corroborated by another study which also reported that 
biomarker screening is underutilized in routine care.  In that study, only 12% of US 
acute-care hospitals ordered the EGFR assay in 2010, which represented 5.7% of 
guideline-directed patients.[9]   Yet, outcomes with erlotinib therapy are correlated with 
EGFR mutation status and therefore dependent on molecular testing.  While unselected 
patients with advanced NSCLC have response rates of 8% to 9% and median 
progression-free survival (PFS) of 3.4 months with erlotinib, those whose tumors 
harbour drug sensitizing EGFR mutations have response rates of 68% and median PFS 
of 12 months on erlotinib.[8]  In a recent trial of first line erlotinib therapy in patients with 
tumors positive for the EGFR drug sensitizing mutations, median overall survival was 
19.3 months.[7]  The lower median OS found in our observational cohort compared to 
the results in that trial may be due, in part, to differences in age and functional status.  
31	  
Still, a three-fold difference in median OS, coupled with the low proportion of patients 
with evidence of molecular testing suggest that molecularly guided therapy is 
underutilized in routine practice.   One way to optimize the value of erlotinib therapy is to 
condition its use on EGFR positive status.  Commercial EGFR mutation assays were 
first marketed in 2005 and many laboratory-developed tests (LDTs) for EGFR mutations 
are available, providing ready access to EGFR testing.[9]    In addition,  ascertainment 
of predictive biomarker status prior to selection of TKI therapy in all patients with non-
squamous, advanced stage NSCLC has been endorsed by professional societies 
including the American Society for Clinical Oncology (ASCO),  the College of American 
Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC),  
the Association for Molecular Pathology (AMP), as well as NCCN.[8, 50, 51] 
Evidence suggests that better value for EGFR TKIs, in terms of return on medical 
spending, is achievable through universal molecular testing of guideline-recommended 
patients.   Handorf et al. conducted a cost effectiveness analysis of EGFR mutation 
testing to inform first-line treatment in patients with stage IV NSCLC in the United 
States.  Compared to standard of care with carboplatin and paclitaxel combination 
chemotherapy, testing followed by erlotinib treatment in EGFR mutation positive tumors, 
or chemotherapy in wild type tumors yielded ICERs in the range of $110,600 to 
$122,200 per QALY.  Compared with carboplatin, pemetrexed and bevacizumab as the 
standard of care, the testing strategy had ICERs of $25,500 to $44,000 per QALY.[17]   
In a separate analysis, we also found that EGFR mutation and anaplastic lymphoma 
kinase (ALK) rearrangement guided therapy in non-squamous, Stage IV NSCLC 
patients yields good value with an ICER of $150,000 per QALY compared to cisplatin-
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pemetrexed treatment in unselected patients.(ref 1st paper)    The effect of EGFR 
mutation guided therapy on the health care budget appears to have a small impact.  In a 
plan of 500,000 members, the budget impact did not exceed $0.019 per member per 
month in one analysis.[52]  Taken as a whole, the return on medical spending for 
erlotinib would be improved by better targeting of patients most likely to benefit from this 
TKI through molecular testing.  
The limitations of our study need to be considered in the interpretation of our 
findings.  We relied on observational data in our analysis, which is subject to selection 
biases.  We mitigated the imbalance between treatment groups with the use of doubly 
robust methods, which included propensity score estimation with 43 potential 
confounders of treatment selection and outcomes.  We included proxy indicators of 
known predictors of therapy choice, such as performance status, and smoking history, 
as well as phenotypic characteristics that have been shown to correlate with EGFR drug 
sensitizing mutations.[8, 30]   We further adjusted for residual confounding and 
unobserved area-level confounders by using a doubly robust estimator, including fixed 
HRR effects.  Still, propensity score methods will estimate a causal effect that is 
unbiased to the extent that there are no omitted variables which confound the 
relationship between treatment and the outcome.   To account for potential omitted 
variable bias, in our sensitivity analyses, we conducted instrumental variable analyses.  
All results yielded consistent findings.  
From an external validity standpoint, the results of our analysis are generalizable 
to most elderly patients (65 years of age and older) who are managed in the community 
setting.  The SEER population is generally representative of the US population.[53]   
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The median age of NSCLC patients at diagnosis is 71 years and two thirds of NSCLC 
patients are 65 or older at the time of diagnosis.[54]   In addition, our analysis is based 
mainly on  patients who were not enrolled in a clinical trial, thus the results are 
generalizable to the majority of patients afflicted by this disease.  However, our analysis 
does not reflect treatment patterns and costs in managed care populations, who have 
been shown to differ systematically from FFS beneficiaries.[55]  Furthermore, the 
results are restricted to direct medical costs and thus do not include time costs, or costs 
due to lost productivity.  These metrics were outside the scope of the present analysis.  
In an era of a growing cost burden of cancer care, the cost of targeted therapies 
has come under increased scrutiny mostly as a response to the sticker shock from drug 
prices.[3-5, 16, 56]   Based on  treatment patterns in routine care, the economic value 
generated by targeted therapies in the setting of advanced NSCLC is unfavorable 
relative to conventional benchmarks.  Improvements in cost-effectiveness may be 
possible using predictive molecular marker testing to identify patients with drug 
sensitizing mutations that predispose to a favorable response to therapy.  Future policy 
efforts aimed at incentivizing molecularly guided therapy should be evaluated towards 
broader implementation of screening for genetic markers.  Such policies may include 
value-based benefit designs that reduce patient cost-sharing with accompanying 
evidence of positive results for EGFR drug sensitizing mutations, or reference pricing 
whereby reimbursement level for targeted therapies to providers is made contingent on 
the evidence base, or guideline recommendations (e.g., with higher reimbursement in 
cases of guideline-concordant care).   
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1.5  Appendix 
Figure 1.A.1. Hazard functions by treatment group.  The vertical lines correspond to the 
cut-point on the K-M survival curve where probability of survival is 20% or less. 
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Figure 1.A.2. Doubly robust survival curves and piecewise exponential model 
calibration. 
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 Table 1.A.1.  Predicted Survival According to Treatment for Unadjusted, Doubly-Robust and Instrumental Variable 
Results.
OLS	   Delta	  
(95%	  CI)	  
IPW,	  doubly	  
robust,	  HRR	  
fixed	  effects	  
Delta	  
(95%	  CI)	  
IPW,	  doubly	  
robust,	  HSA	  
fixed	  effects	  
Delta	  
(95%	  CI)	  
Original	  HRRs	  
for	  local	  area	  
treatment	  
pattern	  IV	  
2SLS	  -­‐	  	  
XTIVREG	  code	  
Delta	  
(95%	  CI)	  
Original	  HSAs	  
for	  local	  area	  
treatment	  
pattern	  IV	  
2SLS	  -­‐	  	  
XTIVREG	  code	  
Delta	  
(95%	  CI)	  
Predicted	  6-­‐month	  survival	  
BSC	   0.223	   .226	   .225	   .201	   .195	  
Chemotherapy	   0.535	   .312	  
(.290,	  .334)	  
.528	   .302	  
(.277,	  .327)	  
.528	   .303	  
(.278,	  .328)	  
.495	   .294	  
(.077,	  .512)	  
.548	   .353	  
(.189,	  .517)	  
Targeted	   0.701	   .166	  
(.140,	  .192)	  
.680	   .152	  
(.119,	  .185)	  
.681	   .153	  
(.120,	  .186)	  
.832	   .337	  
(.130,	  .544)	  
.765	   .217	  
(.040,	  .394)	  
Predicted	  12-­‐month	  survival	  
BSC	   .113	   .112	   .112	   .092	   .083	  
Chemotherapy	   .291	   .178	  
(.158,	  .197)	  
.284	   .172	  
(.150,	  .194)	  
.283	   .171	  
(.150,	  .193)	  
.264	   .172	  
(-­‐.022,	  .367)	  
.293	   .210	  
(.064,	  .358)	  
Targeted	   .432	   .141	  
(.118,	  .164)	  
.418	   .134	  
(.102,	  .166)	  
.418	   .135	  
(.103,	  .168)	  
.541	   .277	  
(.092,	  .462)	  
.515	   .222	  
(.063,	  .380)	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Table 1.A.2.  Predicted Costs According to Treatment for Unadjusted, Doubly-Robust and Instrumental Variable Results. 
Mean	  Predicted	  
6-­‐month	  cost	  
OLS	   Delta	  
(95%	  CI)	  
IPW,	  
doubly	  
robust,	  
OLS,	  
HRR	  
fixed	  
effects	  
Delta	  
(95%	  CI)	  
IPW,	  
doubly	  
robust,	  
OLS,	  
HSA	  
fixed	  
effects	  
Delta	  
(95%	  CI)	  
Original	  
HRRs	  for	  
local	  area	  
treatment	  
pattern	  IV	  
2SLS	  -­‐	  	  
XTIVREG	  
code	  
Delta	  
(95%	  CI)	  
Original	  
HSAs	  for	  
local	  area	  
treatment	  
pattern	  IV	  
2SLS	  -­‐	  	  
XTIVREG	  
code	  
Delta	  
(95%	  CI)	  
Mean	  Predicted	  6-­‐month	  cost	  
BSC	   36,703	   36,533	   36,562	   36,523	   35,421	  
Chemotherapy	   49,834	   13,131	  
(11,671,	  
14,591)	  
49,533	   13,000	  
(11,474,	  14,526)	  
49,437	   12,875	  
(11,354,	  14,397)	  
52,562	   16,039	  
(1,526,	  30,552)	  
55,818	   20,397	  
(9,299,	  31,494)	  
Targeted	   62,932	   13,098	  
(11,367,	  
14,829)	  
60,528	   10,995	  
(9,027,	  12,964)	  
60,380	   10,943	  
(8,919,	  12,967)	  
58,702	   6,140	  
(-­‐7,688,	  19,968)	  
57,019	   1,202	  
(-­‐10,815,	  
13,219)	  
Mean	  Predicted	  12-­‐month	  cost	  
BSC	   41,621	   41,395	   41,376	   40,625	   41,612	  
Chemotherapy	   65,456	   23,835	  
(21,973,	  
25,812)	  
65,051	   23,656	  
(21,443,	  25,	  869)	  
64,968	   23,591	  
(21,355,	  25,828)	  
69,411	   28,785	  
(9,723,	  47,847)	  
71,309	   29,698	  
(15,147,	  44,248)	  
Targeted	   94,268	   28,812	  
(26,395,	  
30,946)	  
89,818	   24,767	  
(21,652,	  27,883)	  
89,933	   24,966	  
(21,781,	  28,151)	  
90,243	   20,832	  
(2,670,	  38,995)	  
85,400	   14,091	  
(-­‐1,666,	  29,847)	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2.1 Abstract 
Purpose 
Patients who test positive for epidermal growth factor receptor (EGFR) somatic 
alterations derive significant clinical benefits from erlotinib, but the extent to which 
individual lung cancer patients undergo molecular testing in routine care is not known. 
Prevalence and factors associated with testing in routine care were determined in 
elderly patients with stage IV NSCLC from SEER-Medicare. 
Patients and Methods 
We identified patients with squamous- and non-squamous-cell diagnosis of Stage IV 
NSCLC occurring between 2007 and 2009.  The main outcome, molecular testing, was 
identified with relevant medical billing codes.  Multivariable logistic regression was used 
to assess characteristics that independently determine the choice of molecular testing. 
Results 
Among 7,678 patients, only 4.9% underwent a molecular test.  The strongest predictor 
of molecular testing was treating physician affiliation with a NCI cancer center (adjusted 
proportion: 9.9% at NCI cancer centers vs. 4.7% outside).  Among the minority of 
patients who were tested, molecular testing was independently associated with 
phenotypic enrichment using known correlates of EGFR mutations (female gender, East 
Asian origin, non-squamous-cell histology, no history of COPD which was a proxy for 
being a non-smoker).  Older age, enrollment in Medicaid, and admission to hospice 
decreased the likelihood of testing but increased the probability of first-line erlotinib 
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therapy.  Among the 6.5% of patients who were treated with first-line erlotinib, only 8.9% 
of patients were tested prior to erlotinib initiation. 
Conclusion 
During the study period, the vast majority of lung cancer patients did not undergo 
molecular testing in routine care.  Actions towards population-wide dissemination of 
molecular testing through provider education and payer mandates to submit molecular 
test results prior to reimbursement for targeted therapies may encourage adoption of 
these technologies.   
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2.2  Introduction 
Treatment outcomes in advanced lung cancer have plateaued at a median 
overall survival (OS) of 10 to 12 months with traditional chemotherapy combinations, but 
targeted treatment innovations are changing the landscape of prognosis in lung cancer. 
The burden of lung cancer is substantial.  It is the leading cause of cancer related 
mortality, representing 27% of all cancer deaths.  In the United States alone, 
approximately 160,000 patients will die from this disease in 2014.1  Evidence points to 
significant clinical benefits from therapies that target molecular pathways in patients 
who test positive for oncogenic driver mutations, but the extent to which individual lung 
cancer patients undergo molecular testing in routine care is not known.2,3 
Patients whose tumors are identified to carry epidermal growth factor receptor 
(EGFR) somatic alterations and who are treated with erlotinib have shown remarkable 
improvements in median progression free survival (PFS) compared to chemotherapy 
alone, 9.4 vs. 5.2 months.2   On the other hand, controlled trial-based evidence 
suggests that conventional chemotherapy confers better outcomes in patients with 
EGFR wild type tumors compared to EGFR TKI therapy.3-6   EGFR gene mutations are 
more prevalent in non-squamous tumors, women, patients of East Asian origin and in 
those with no history of smoking.4  While phenotypic characteristics associated with 
these gene mutations have been elucidated, these attributes do not adequately 
discriminate between EGFR mutation positive and wild type tumors.  There is a general 
consensus that phenotypic characteristics should not be used to select or exclude 
patients for treatment or molecular testing.4  By 2007, the National Comprehensive 
Cancer Network (NCCN) Lung Cancer guidelines acknowledged the predictive value of 
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EGFR gene mutations for response to erlotinib.10  Beginning in 2010, guideline 
recommendations endorsed population-wide molecular screening for EGFR gene 
mutations in all advanced non-squamous, stage IV NSCLC cases to inform treatment 
choices.4,7,8   
In this analysis, our goal was to estimate the prevalence of molecular screening 
in routine care and to assess factors that determine the choice to conduct molecular 
testing in a nationally representative cohort of elderly patients with stage IV NSCLC. 
2.3 Methods 
2.3.1 Study Participants 
We identified patients with pathologically confirmed squamous cell and non-
squamous cell incident diagnosis of Stage IV NSCLC occurring between January 1, 
2007 and December 31, 2009.   We used data from the National Cancer Institute’s 
Surveillance, Epidemiology, and End Results (SEER) program linked to Medicare Part 
A, B and D claims.  The SEER program collects information from 17 cancer registries, 
which cover approximately 28% of the US population.9  
To ascertain comorbidity burden and pre-diagnosis medical costs at baseline and 
to determine lung cancer treatment practice patterns after diagnosis, patients who were 
continuously enrolled in Medicare Part A and B beginning eight months prior to 
diagnosis and those who were also eligible for Parts A, B and D one year post diagnosis 
were included.   To ensure completeness of claim history, patients who were in a health 
maintenance organization (HMO) plan at any point during the observation period were 
excluded.  In addition, patients were excluded if they had other concurrent cancers 
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diagnosed either before or after the index NSCLC diagnosis.  In the primary analysis, 
we compared patient groups according to whether or not they underwent a molecular 
test after diagnosis and prior to treatment initiation (Figure 2.1).   In a secondary 
analysis in which we examined determinants of first-line therapy, we classified patients 
into three groups based on first-line treatment initiation within 120 days of diagnosis: 1) 
erlotinib group;  2) chemotherapy group, which comprised of patients who were treated 
with chemotherapy, with or without bevacizumab; 3) remaining patients  were 
categorized to the best supportive care (BSC) group, if there was no evidence of 
systemic therapy receipt (chemotherapy or targeted therapy) within 120 days from 
diagnosis.   
Figure 2.1. Flow diagram of study cohort 
33	  068	  	  PaQents	  diagnosed	  with	  ﬁrst	  and	  only	  
cancer;	  	  
Stage	  IV	  NSCLC	  between	  2007-­‐2009	  	  	  
377	  with	  a	  molecular	  test	  7	  301	  with	  no	  molecular	  test	  
25	  390	  Excluded	  
6	  420	  Age	  at	  diagnosis	  <66	  y	  
2	  039	  Not	  pathologically	  conﬁrmed	  
5	  340	  Not	  enrolled	  in	  Medicare	  Part	  A	  
and	  B	  
6	  308	  Enrolled	  in	  Medicare	  HMO	  
5	  283	  No	  Medicare	  Part	  D	  Coverage	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2.3.2  Molecular Test Identification 
During the observation period between 2007 and 2010, a unique Healthcare 
Common Procedure Coding System (HCPCS) code to allow identification of EGFR 
mutation testing did not exist.  Instead, providers deferred to a ‘stacking’ method to bill 
for EGFR gene mutation analysis using HCPCS codes that represented the steps and 
techniques used in performing a molecular pathology test.  We used the Genzyme 
Genetics (the sole distributor of the commercial EGFR assay in 2010) test stack of 
HCPCS codes to identify any claim in the outpatient file with at least one of these codes 
(see Appendix).  Even in 2010, the vast majority of laboratories (99%) were not 
accredited by the Clinical Laboratory Improvement Amendments (CLIA) program to 
conduct cytogenetic testing and ordered molecular testing through commercial 
reference laboratories.10  Those that were accredited and conducted EGFR mutation 
analysis with laboratory developed tests (LDTs) also used the ‘stacking’ method for 
billing purposes with a combination of the HCPCs codes outlined in the 
Appendix.(personal communication: J. Fahey, December 2013).   We also flagged 
HCPCS code 83912  (‘Interpretation and report’) in the physician claims file, as an 
indicator of a molecular test.  This code corresponds to the professional component of 
the molecular test bill and appears in the physician file irrespective of whether the test 
was conducted as part of an inpatient or an outpatient encounter. (personal 
communication: J.Fahey, December 2013)   Therefore, while a specific molecular test, 
such as KRAS or EGFR gene mutation analysis, could not be identified in the claims 
during the index period, performance of any molecular test was identifiable.  The index 
period for molecular test classification encompassed claims with dates ranging from 45 
days prior to diagnosis through 30 days after the start of first line therapy, or 150 days 
53	  
after diagnosis for patients who were managed with BSC.  Both the index period and 
the composition of our analytic cohort, which comprised newly diagnosed stage IV 
NSCLC patients with lung cancer being the first and only cancer, mitigated 
misclassification bias of a molecular test order for other conditions.  
2.3.3  First-line Treatment Classification 
We identified cancer directed systemic therapy use from Medicare claims.  
Claims for individual drugs were flagged using HCPCS codes and National Drug Codes 
(NDC) in the outpatient, physician, durable medical equipment and Medicare Part D 
files using previously described methods.11,12 The date of the first systemic therapy 
claim within 120 days from diagnosis was used to define the start date of first line 
treatment.13    
 2.3.4  Patient and Practice Characteristics 
We identified several potential factors that may impact decisions surrounding 
molecular testing and first line treatment choice.  These spanned phenotypic 
characteristics that are correlated with presence of drug sensitizing EGFR gene 
mutations in NSCLC - race, female gender, histology, and smoking history using 
presence of COPD as a proxy indicator.  Additional characteristics included: age; 
ethnicity; comorbidity score; hospice enrollment after diagnosis; marital status; presence 
of brain metastases; enrollment in Medicaid; sample acquisition method (histology, 
cytology); urban residence; US Census tract level household income, college education; 
year of diagnosis and SEER Region. 14  A proxy measure of poor performance status 
(PS) prior to diagnosis was also included based on bills starting from 8 months prior to 
diagnosis.  Services typically associated with poor functional status were coded as 
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dummies (inpatient or skilled nursing facility stay, home health visit, use of home 
oxygen, or ADL aids (any bill for equipment such as walkers, hospital beds, 
wheelchairs), personal communication: E. Lamont, November, 2013).15  These 
indicators were summed up as a count (0, 1, 2+) to derive the proxy PS index.  
Furthermore, we summed up medical spending for the eight-month period prior to 
diagnosis as another proxy indicator of health status (excluding 2 months most proximal 
to diagnosis to exclude costs related to cancer diagnosis and staging).  Practice 
characteristics, namely National Cancer Institute (NCI) cancer center designation, 
cooperative group affiliation, and hospital teaching status, were also included. 
2.3.5  Statistical Methods 
Bivariate analyses using the χ2 test were conducted to compare the distributions 
in baseline characteristics according to molecular test status.   Next, we used logistic 
regression to identify patient and practice characteristics associated with a molecular 
test order.    Included in the model were variables with a p-value <0.20 on bivariate 
testing.   Marginal, adjusted probabilities were calculated for each variable in the 
multivariable model.    A parallel method was used to construct a multivariable model 
using multinomial logistic regression to identify patient, disease and practice 
characteristics associated with first line treatment (erlotinib, chemotherapy, BSC; see 
Appendix).   We also conducted survival analyses to explore the relationship between 
time to hospice admission from initiation of first-line therapy and molecular testing.  
Kaplan-Meier survival curves were generated and subgroups were compared using the 
log rank test.  All analyses were conducted using SAS, version 9.2. 
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2.4  Results 
2.4.1  Baseline Characteristics 
Among 7,678 incident cases diagnosed with Stage IV non-squamous and 
squamous cell NSCLC between 2007 and 2009, who met our inclusion criteria (Figure 
2.1), only 377 (4.9%) underwent a molecular test.  Table 2.1 summarizes patient and 
practice characteristics according to whether or not a molecular test was performed.  
Among patients who were tested compared to those who were not, a higher proportion 
were females (58.4% vs. 51.2%), of East Asian origin (11.4% vs. 7.2%), with no history 
of COPD (a proxy indicator of smoking, 84.9% vs. 71.5%) and had non-squamous cell 
tumors (88.6% vs. 76.3%).  In addition, younger patients, those with no proxy indicators 
of poor PS, and no comorbidities had a higher likelihood of being tested.  Hospice 
admission after diagnosis and enrollment in Medicaid were both associated with a lower 
probability of a molecular test.  Persons treated at NCI designated cancer centers and 
at practices with a cooperative group affiliation were also more likely to undergo 
molecular testing (10.1% vs. 2.0%, and 30.8% vs. 16.1%, respectively).   A higher 
proportion of patients who received any systemic cancer-directed therapy (7.8%) 
underwent a molecular test compared to those managed with BSC (1.7%), but 
unadjusted prevalence of testing was low across all treatment categories.   
56	  
Table 2.1. Characteristics according to molecular testing status. 
Characteristic* Molecular Test 
(n=377) 
No Molecular Test 
(n=7,301) 
Age at diagnosis, years           66-69 
70-74 
75-79 
80-84 
85+ 
107 (28.4) 
104 (27.6) 
90 (23.9) 
59 (15.7) 
17 (4.5) 
1,636 (22.4) 
1,950 (26.7) 
1,697 (23.2) 
1,257 (17.2) 
761 (10.4) 
Gender              Female 220 (58.4) 3,737 (51.2) 
Race        White 
Black 
East Asian 
Other 
314 (83.3) 
14   (3.7) 
43 (11.4) 
6   (1.6) 
5,951 (81.5) 
753 (10.3) 
525   (7.2) 
72   (1.0) 
Ethnicity Hispanic 19 (5.0) 414   (5.7) 
Baseline PS indicator, count 0 
1 
2+ 
220 (58.4) 
100 (26.5) 
57 (15.1) 
3,141 (43.0) 
2,186 (29.9) 
1,974 (27.0) 
Marital Status       Married 206 (54.6) 3,256 (44.6) 
Comorbidity Index  0 
1 
2 
3+ 
262 (69.5) 
59 (15.7) 
28   (7.4) 
28   (7.4) 
4,210 (57.7) 
1,314 (18.0) 
682   (9.3) 
1,095 (15.0) 
COPD Yes 
No 
57 (15.1) 
320 (84.9) 
2,079 (28.5) 
5,222 (71.5) 
Histology Non-squamous cell 
Squamous cell 
334 (88.6) 
43 (11.4) 
5,573 (76.3) 
1,728 (23.7) 
Sample acquisition method  Histology 
Cytology 
309 (82.0) 
68 (18.0) 
5,440 (74.5) 
1,861 (25.5) 
Brain Metastases Present 69 (18.3) 1,296 (17.8) 
Hospice admission               Yes 149 (39.5) 4,370 (59.9) 
Prior Year Medicaid Yes 72 (19.1) 2,617 (35.8) 
First-line Treatment                                                Erlotinib 43 (11.4) 457  (6.3) 
Chemotherapy with/without bevacizumab 270 (61.7) 3,244 (44.4) 
Best supportive care 64 (17.0) 3,600 (49.3) 
Urban Residence Yes 355 (94.2) 6,299 (86.3) 
Cooperative Group affiliation          Yes 116 (30.8) 1,175 (16.1) 
NCI Cancer Center Yes 38 (10.1) 146   (2.0) 
Teaching Hospital Yes 102 (27.1) 1,053 (14.4) 
College education (census tract quintile) 1 (low) 
2 
3 
4 
5 (high) 
34   (9.0) 
58 (15.4) 
80 (21.2) 
77 (20.4) 
128 (34.0) 
1,733 (23.7) 
1,551 (21.2) 
1,354 (18.6) 
1,350 (18.5) 
1,309 (17.9) 
Income (census tract quintile)              1 (low) 
2 
3 
4 
5 (high) 
40 (10.6) 
54 (14.3) 
79  (21.0) 
78  (20.7) 
126 (33.4) 
1,784 (24.4) 
1,573 (21.5) 
1,381 (18.9) 
1,320 (18.1) 
1,239 (17.0) 
1-yr Cost pre diagnosis (quintile) 1 (low) 
2 
3 
4 
5 (high) 
63 (16.7) 
87 (23.1) 
92 (24.4) 
70 (18.6) 
65 (17.2) 
1,176 (16.1) 
1,436 (19.7) 
1,460 (20.0) 
1,583 (21.7) 
1,646 (22.5) 
Year of diagnosis               2007 
2008 
2009 
40 (10.6) 
88 (23.3) 
249 (66.1) 
2,538 (34.8) 
2,447 (33.5) 
2,316 (31.7) 
Region Northeast 
South 
Midwest 
West 
122 (32.4) 
52 (13.8) 
35 (9.3) 
168 (44.6) 
1,321 (18.1) 
2,123 (29.1) 
1,155 (15.8) 
2,702 (37.0) 
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2.4.2  Predictors of Molecular Testing 
Table 2.2 summarizes the significant characteristics, which determined the 
decision to perform a molecular test.  First, the strongest independent predictor of 
molecular testing was affiliation with a NCI cancer center (adjusted proportion: 9.9% at 
NCI cancer centers vs. 4.7% outside).  Second, the multivariable prediction model 
suggested that molecular testing was also associated with phenotypic enrichment using 
known correlates of EGFR mutations.  The adjusted predicted probabilities of 
undergoing a molecular test by phenotype were: 5.5% for females vs. 4.3% for males; 
3.3% for non-squamous cell vs. 2.3% for squamous cell histology; 8.0% for East Asian 
vs. 3.1% for Black racial origin for example; and 5.3% for no COPD (a proxy indicator of 
smoking status) vs. 3.4% for COPD, respectively (p-values <0.01).  Notably among all 
gender-race groups, East Asian, female patients had the highest probability of being 
tested and also of initiating first-line erlotinib therapy (Figure 2.2).  But, even among this 
patient subgroup, the adjusted proportions with testing and TKI treatment were only 
8.9% and 14.2%, respectively.  As expected, histological tissue samples were 
associated with a higher probability of molecular testing than cytological samples 
(adjusted proportions: 5.4% vs. 3.4%).   
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Table 2.2. Predictors of molecular testing 
Characteristic Odds Ratio (OR) 95% CI for OR P-value 
Adjusted 
Probability of a 
Molecular Test (%) 
Gender 
Male 
Female 
Reference 
1.35 
Reference 
1.08, 1.69 <0.01 
4.3 
5.5 
Age at diagnosis, years 
66-69 
70-74 
75-79 
80-84 
85+ 
Reference 
0.82 
0.80 
0.68 
0.35 
Reference 
0.61, 1.11 
0.59, 1.09 
0.48, 0.96 
0.20, 0.60 
0.20 
0.16 
0.03 
<0.01 
6.1 
5.3 
4.6 
4.0 
3.4 
Race 
White 
Black 
East Asian 
Other 
Reference 
0.61 
1.91 
1.33 
Reference 
0.35, 1.08 
1.28, 2.85 
0.53, 3.37 
0.10 
<0.01 
0.55 
4.8 
3.1 
8.0 
6.5 
Baseline PS indicator 
0 
1 
2+ 
Reference 
0.82 
0.70 
Reference 
0.63, 1.06 
0.50, 0.96 
0.13 
0.03 
5.4 
4.8 
3.7 
Histology 
Non-squamous cell 
Squamous cell 
Reference 
0.47 
Reference 
0.34, 0.66 <0.01 
3.3 
2.3 
COPD 
Yes 
No 
Reference 
1.71 
Reference 
1.26, 2.33 <0.01 
3.4 
5.3 
Sample acquisition method 
Histology 
Cytology 
Reference 
0.58 
Reference 
0.43, 0.77 <0.01 
5.4 
3.4 
Prior year, Medicaid 
Yes 
No 
Reference 
2.07 
Reference 
1.52, 2.82 <0.01 
3.0 
5.8 
Income (census tract quintile) 
1 (Low) 
2 
3 
4 
5 (High) 
Reference 
1.28 
1.71 
1.53 
2.31 
Reference 
0.83, 1.97 
1.13, 2.58 
1.00, 2.34 
1.53, 3.47 
0.26 
0.01 
<0.05 
<0.01 
3.4 
4.0 
4.7 
5.5 
6.3 
NCI Cancer Center 
No 
Yes 
Reference 
2.59 
Reference 
1.62, 4.12 <0.01 
4.7 
9.9 
Cooperative Group Affiliation 
No 
Yes 
Reference 
1.39 
Reference 
1.05, 1.84 0.02 
4.6 
6.1 
Hospice 
No 
Yes 
Reference 
0.49 
Reference 
0.39, 0.62 <0.01 
6.5 
3.6 
Region 
Northeast 
South 
Midwest 
West 
Reference 
0.41 
0.39 
0.69 
Reference 
0.28, 0.59 
0.26, 0.59 
0.52, 0.91 
<0.01 
<0.01 
0.01 
7.0 
3.3 
3.1 
5.3 
Year of diagnosis 
2007 
2008 
2009 
Reference 
2.44 
7.03 
Reference 
1.66, 3.59 
4.97, 9.95 
<0.01 
<0.01 
1.6 
3.7 
9.0 
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Patient characteristics that are not correlated with EGFR mutation status, namely 
younger age and better baseline PS, also affected the likelihood of molecular testing.   
For example, the youngest patients in our cohort (aged 66 to 69 years) were more likely 
to have a molecular test (6.1%) compared to the age group 80 to 84 years (4.0%).  
Interestingly, an opposite relationship emerged between age and the likelihood of 
receipt of first-line erlotinib (Figure 2.2).  Older age was associated with a higher 
probability of treatment with the oral TKI (adjusted proportion: 3.8% for age group 66 to 
69 years vs. 9.0% for age group 80 to 84 years).  Persons with no indicators of a poor 
PS had a 5.4% adjusted probability of testing compared to 3.7% in those with 2 or more 
indicators of poor PS.   Controlling for age, indicators of a poor PS, and other significant 
characteristics, admission to a hospice after diagnosis of NSCLC was a strong 
determinant of both molecular testing and initiation of first-line erlotinib therapy.  
Patients who enrolled in hospice care had a significantly lower likelihood of undergoing 
molecular testing (adjusted proportion: 3.6% with vs. 6.5% without hospice admission, 
p-value <0.01), but a significantly higher likelihood of initiating first-line erlotinib therapy 
(7.2% with vs. 5.6% without hospice admission, p-value <0.01).    
NCI Cancer Center designation notwithstanding, other practice characteristics 
that independently determined testing included Medicaid enrollment and cooperative 
group affiliation.  Notably, Medicaid enrollment was a negative independent predictor of 
molecular testing (adjusted proportion: 3.0% with Medicaid vs. 5.8% without), but it was 
a positive predictor of first-line erlotinib therapy (adjusted proportion: 7.4% with 
Medicaid vs. 6.1% without, Figure 2.2).   
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Figure 2.2.  Adjusted relationships between patient and practice characteristics and 
receipt of first-line erlotinib therapy (yello bars) and undergoing a molecular test (blue 
bars) for Stage IV NSCLC.  Proportions are the average predicted probabilities adjusted 
for other covariates in regression models (Table 2.2 and Appendix).  
0%	   2%	   4%	   6%	   8%	   10%	  12%	  14%	  16%	  
East	  Asian/
Female	  
East	  Asian/
Male	  
White/
Female	  
Black/
Female	  
White/Male	  
Black/Male	  
0%	   2%	   4%	   6%	   8%	  10%	  12%	  14%	  16%	  
Squamous	  Cell	  
Non-­‐squamous	  Cell	  
COPD	  
No	  COPD	  
0%	   2%	   4%	   6%	   8%	   10%	  12%	  14%	  16%	  
85+	  
80-­‐84	  
75-­‐79	  
70-­‐74	  
66-­‐69	  
adjusted	  proporQon	  receiving	  intervenQon	  
0%	   2%	   4%	   6%	   8%	  10%	  12%	  14%	  16%	  
NCI	  Cancer	  Center	  
non-­‐NCI	  Cancer	  
Center	  
CooperaQve	  Group	  
non-­‐CooperaQve	  
Group	  
Medicaid	  
No	  Medicaid	  
adjusted	  proporQon	  receiving	  intervenQon	  
1st-­‐line	  
Erlo-nib	  
Molecular
Test	  
61	  
 Likewise, more patients treated at practices with a cooperative group affiliation 
underwent molecular testing (adjusted proportion: 6.1% vs. 4.6%), but fewer were 
treated with first-line erlotinib (adjusted proportion: 6.8% vs. 7.2%) compared to patients 
from other centers.   Furthermore, some regions appeared to be earlier adopters of 
molecular testing in lung cancer, albeit the rates of utilization were low across all 
regions.   For instance, in the Northeast, which ranked highest in molecular test 
adoption rates, the adjusted proportion was only 7.0%.  Although we did observe a 
significant time trend for molecular testing after controlling for other predictors, still only 
9.0% of patients were tested in 2009, from a low of 1.6% in 2007.    
Given that hospice admission emerged as a significant indicator of both 
molecular testing and of first-line erlotinib therapy initiation, we explored the association 
between the start of treatment and time to admission to a hospice and according to 
whether or not molecular testing was performed (Figure 2.3).  Among patients who 
received hospice care, the median time to hospice admission was 3.3 months after start 
of first-line erlotinib and 6.6 months after initiation of chemotherapy-based treatment (p-
value<0.0001).  The median time to hospice admission from start of first-line erlotinib 
was 3.2 months among persons who did not undergo molecular testing (n=310) and 8.9 
months among those who were tested (n=20), p-value=0.03.   Twenty-five percent of 
patients who did not have molecular testing were admitted to a hospice approximately 
within one month (35 days) after starting first-line erlotinib compared to 2.8 months if 
they were tested (Figure 2.3).   
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Figure 2.3.  Kaplan-Meier curves depicting time to hospice admission from initiation of 
first line therapy among Stage IV NSCLC patients admitted to a hospice.   
A B 
(A) Time from first-line erlotinib initiation (blue curve, n=330) and from first-line 
chemotherapy initiation (red curve, n=2304) to hospice admission.  (B) Time from first-
line erlotinib initiation among patients with a molecular test (red curve, n=20) and those 
without a molecular test (blue curve, n=310) to hospice admission. 
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2.5  Discussion 
Molecularly guided therapy has revolutionized the prognosis of lung cancer.  
Using the SEER-Medicare linked data, we evaluated practice patterns of molecular 
testing in routine care among patients with stage IV NSCLC diagnosed between 2007 
and 2009.  In our population-based study, only 4.9% of eligible patients underwent 
molecular testing.   The determination to conduct molecular testing was influenced by 
phenotypic characteristics that are correlated with EGFR mutations, younger age, and 
better performance status.  Patients enrolled in Medicaid and those admitted to hospice 
after diagnosis were significantly less likely to undergo molecular testing, but had a 
higher likelihood of initiating first-line erlotinib therapy.  The strongest predictor of having 
a molecular test was receipt of care at an NCI designated cancer center.  
Corroborating evidence of the underuse of predictive biomarker screening in lung 
cancer comes from a hospital-level analysis by Lynch et al.10  In that paper, the authors 
estimated that in 2010, only 12% of US acute care hospitals ordered an EGFR assay, 
which represented 5.7% of newly diagnosed lung cancer patients.  From our analysis of 
individual patients, the adjusted proportion of patients diagnosed in 2009 who had any 
type of molecular test was 9.0%.  This estimate may include non-EGFR molecular tests, 
such as KRAS gene mutation testing.  Still, it appears that molecular testing is 
performed in a minority of patients who are treated in routine care.  Even at centers of 
excellence, the NCI cancer centers, the adjusted proportion of patients who were tested 
was only 9.9%. These findings call for a closer examination of the barriers to 
dissemination of molecular testing.  For example, new evidence suggests that 
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physicians may have a low confidence in genomic knowledge.16  These knowledge 
gaps may signal important patient-access barriers at the provider level.  
Our results further indicate that in routine care clinical enrichment criteria were 
used to select patients for molecular testing.  All clinical characteristics associated with 
EGFR mutations (female gender, smoking history, East Asian race) were independent 
predictors of molecular testing.   Such clinical enrichment practices do not have 
adequate discriminatory power as a pre-screening tool.4  One study reported that 
basing molecular screening on clinical enrichment criteria may lead to undiagnosing 
over half of patients who carry drug sensitizing mutations.17 With the advent of 
multiplexed test platforms, population-wide screening for predictive biomarkers in lung 
cancer followed by molecularly guided therapy is a cost effective approach 
(D.Romanus, Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-
Small Cell Lung Cancer. Manuscript submitted for publication).   At the payer level, 
payment for targeted therapies with identifiable predictive molecular markers could be 
made contingent on evidence of test results to encourage molecularly guided therapy.   
First-line therapy with erlotinib in patients harboring EGFR sensitizing mutations 
is the accepted standard of care.7,18   Utilization of first-line TKI therapy in unselected 
patients is controversial.3 In our analysis, only 8.6% of patients had a molecular test 
prior to initiation of first-line erlotinib.  Among patients on first-line erlotinib, 66% were 
admitted to a hospice.  In unselected patients, the median time to hospice admission 
was 3 months and a quarter of patients were admitted within approximately one month 
from initiation of first-line erlotinib.  First-line treatment with erlotinib in unselected 
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patients and its value in the setting of an imminent hospice admission warrant closer 
examination in future research.   
Several limitations need to be taken into account when interpreting our results.  
We were unable to categorize tests by specific molecular markers due to the lack of 
billing codes that would identify each genetic mutation tested.   We flagged any code 
that was part of the stack of codes used for billing for an EGFR gene mutation test 
during the period we analyzed to indicate that a molecular test was conducted.  Even if 
our estimates represent the upper bound of EGFR mutation testing to inform first line 
therapy, our results suggest a gross underutilization of molecularly guided therapy.  This 
analysis was based on a cohort of elderly patients with fee-for-service (FFS) and 
Medicare Part D benefits.  While two-thirds of lung cancer patients are older than 65 at 
time of diagnosis, beneficiaries of FFS and Medicare D coverage may differ 
systematically from those in Medicare Advantage.19,20  
Using the most recent SEER-Medicare data, we found that molecularly guided 
therapy was underutilized in routine care of patients diagnosed with advanced NSCLC 
between 2007 and 2009.  The minority of patients who did undergo molecular testing 
(4.9%) appeared to be selected for testing based on clinical enrichment criteria and 
nonmedical factors, such as practice setting and socioeconomic status.  Actions 
towards population-wide dissemination of molecular testing through provider education 
and payer mandates to submit molecular test results prior to reimbursement for targeted 
therapies may encourage adoption of these technologies.  Future studies should be 
conducted to evaluate the impact of recent guideline recommendations for population-
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wide EGFR mutation screening on the dissemination of genomic testing and molecularly 
guided therapy.4,7 
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2.7  Appendix 
Table 2.A.1. Codes Used in Defining Molecular Tests. 
CARRIER	  CLAIMS	  
83912 MOLECULAR	  DIAGNOSTICS;	  INTERPRETATION	  AND	  REPORT 
OUTPATIENT	  CLAIMS	  
83890 MOLECULAR	  DIAGNOSTICS;	  MOLECULAR	  ISOLATION	  OR	  EXTRACTION,	  EACH	  NUCLEIC	  ACID	  TYPE	  (IE,	  DNA	  OR	  
RNA) 
83891 MOLECULAR	  DIAGNOSTICS;	  ISOLATION	  OR	  EXTRACTION	  OF	  HIGHLY	  PURIFIED	  NUCLEIC	  ACID,	  EACH	  NUCLEIC	  
ACID	  TYPE	  (IE,	  DNA	  OR	  RNA) 
83892 MOLECULAR	  DIAGNOSTICS;	  ENZYMATIC	  DIGESTION,	  EACH	  ENZYME	  TREATMENT 
83894 MOLECULAR	  DIAGNOSTICS;	  SEPARATION	  BY	  GEL	  ELECTROPHORESIS	  (EG,	  AGAROSE,	  POLYACRYLAMIDE),	  
EACH	  NUCLEIC	  ACID	  PREPARATION 
83896 MOLECULAR	  DIAGNOSTICS;	  NUCLEIC	  ACID	  PROBE,	  EACH 
83898 MOLECULAR	  DIAGNOSTICS;	  AMPLIFICATION,	  TARGET,	  EACH	  NUCLEIC	  ACID	  SEQUENCE 
83900 MOLECULAR	  DIAGNOSTICS;	  AMPLIFICATION,	  TARGET,	  MULTIPLEX,	  FIRST	  2	  NUCLEIC	  ACID	  SEQUENCES 
83901 MOLECULAR	  DIAGNOSTICS;	  AMPLIFICATION,	  TARGET,	  MULTIPLEX,	  EACH	  ADDITIONAL	  NUCLEIC	  ACID	  
SEQUENCE	  BEYOND	  2	  (LIST	  SEPARATELY	  IN	  ADDITION	  TO	  CODE	  FOR	  PRIMARY	  PROCEDURE) 
83902 MOLECULAR	  DIAGNOSTICS;	  REVERSE	  TRANSCRIPTION 
83903 MOLECULAR	  DIAGNOSTICS;	  MUTATION	  SCANNING,	  BY	  PHYSICAL	  PROPERTIES	  (EG,	  SINGLE	  STRAND	  
CONFORMATIONAL	  POLYMORPHISMS	  [SSCP],	  HETERODUPLEX,	  DENATURING	  GRADIENT	  GEL	  
ELECTROPHORESIS	  [DGGE],	  RNA’ASE	  A),	  SINGLE	  SEGMENT,	  EACH 
83904 MOLECULAR	  DIAGNOSTICS;	  MUTATION	  IDENTIFICATION	  BY	  SEQUENCING,	  SINGLE	  SEGMENT,	  EACH	  
SEGMENT 
83907 MOLECULAR	  DIAGNOSTICS;	  LYSIS	  OF	  CELLS	  PRIOR	  TO	  NUCLEIC	  ACID	  EXTRACTION	  (EG,	  STOOL	  SPECIMENS,	  
PARAFFIN	  EMBEDDED	  TISSUE),	  EACH	  SPECIMEN 
83909 MOLECULAR	  DIAGNOSTICS;	  SEPARATION	  AND	  IDENTIFICATION	  BY	  HIGH	  RESOLUTION	  TECHNIQUE	  (EG,	  
CAPILLARY	  ELECTROPHORESIS),	  EACH	  NUCLEIC	  ACID	  PREPARATION 
83914 MUTATION	  IDENTIFICATION	  BY	  ENZYMATIC	  LIGATION	  OR	  PRIMER	  EXTENSION,	  SINGLE	  SEGMENT,	  EACH	  
SEGMENT	  (EG,	  OLIGONUCLEOTIDE	  LIGATION	  ASSAY	  [OLA],	  SINGLE	  BASE	  CHAIN	  EXTENSION	  [SBCE],	  OR	  
ALLELE-­‐SPECIFIC	  PRIMER	  EXTENSION	  [ASPE]) 
83912	   MOLECULAR	  DIAGNOSTICS;	  INTERPRETATION	  AND	  REPORT	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Table 2.A.2. Predictors of first line erlotinib therapy. 
Variable 
OR** 
95% CI 
for OR 
Gender Male 
Female 
Reference 
2.16 
Reference 
1.72, 2.70 
Age at diagnosis, years  66-69 
70-74 
75-79 
80-84 
85+ 
Reference 
1.36 
2.28 
4.35 
9.08 
Reference 
0.96, 1.92 
1.63, 3.19 
3.09, 6.14 
6.01, 13.73 
Race White 
Black 
East Asian 
Other 
Reference 
0.98 
4.50 
2.44 
Reference 
0.63, 1.52 
3.26, 6.22 
1.01, 5.88 
Comorbidity Index  0 
1 
2 
3+ 
Reference 
1.20 
1.18 
1.27 
Reference 
0.91, 1.59 
0.82, 1.71 
0.90, 1.80 
Baseline PS indicator 0 
1 
2+ 
Reference 
1.01 
1.25 
Reference 
0.79, 1.29 
0.95, 1.64 
Histology Non-squamous cell 
Squamous cell 
Reference 
0.56 
Reference 
0.42, 0.75 
Brain metastases  No 
Yes 
Reference 
1.37 
Reference 
1.04, 1.81 
COPD No 
Yes 
Reference 
1.16 
Reference 
0.89, 1.50 
Molecular test prior to treatment  No 
Yes 
Reference 
1.22 
Reference 
0.84, 1.77 
Prior year, Medicaid Yes 
No 
Reference 
0.60 
Reference 
0.47, 0.76 
Marital status  Not married 
Married 
Reference 
0.97 
Reference 
0.77, 1.21 
Income (census tract quintile)    1 (Low) 
2 
3 
4 
5 (High) 
Reference 
1.15 
1.21 
1.23 
1.32 
Reference 
0.83, 1.60 
0.86, 1.69 
0.88, 1.73 
0.93, 1.86 
NCI Cancer Center          No 
Yes 
Reference 
1.15 
Reference 
0.53, 2.47 
Cooperative Group Affiliation             No 
Yes 
Reference 
0.25 
Reference 
0.18, 0.34 
Hospice  No 
Yes 
Reference 
1.79 
Reference 
1.42, 2.26 
Region Northeast 
South 
Midwest 
West 
Reference 
0.85 
0.67 
0.90 
Reference 
0.60, 1.18 
0.45, 0.99 
0.67, 1.22 
*multivariable, multinomial logistic model controlled for all variables in the table
** compared to first line chemotherapy 
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3.1  Abstract 
Purpose 
Population-wide screening for epidermal growth factor receptor (EGFR) mutations and 
anaplastic lymphoma kinase (ALK) gene rearrangements to inform cancer therapy in 
non-small cell lung cancer (NSCLC) is recommended by guidelines.  We estimated 
cost-effectiveness of multiplexed predictive biomarker screening in metastatic NSCLC 
from a societal perspective in the US. 
Patients and Methods 
We constructed a microsimulation model to compare the life expectancy and costs of 
multiplexed testing and molecularly guided therapy vs treatment with cisplatin-
pemetrexed (CisPem).  All testing interventions included a two-step algorithm of 
concurrent EGFR mutation and ALK overexpression testing with immunohistochemistry 
(IHC) followed by ALK rearrangement confirmation with a fluorescence in situ 
hybridization (FISH) assay for IHC positive results.  Three strategies were included:  
‘Test-treat’ approach, where molecularly guided therapy was initiated after obtainment 
of test results; ‘Empiric switch therapy’, with concurrent initiation of CisPem and testing 
and immediate switch to test-result conditional treatment after one cycle of CisPem; and 
‘Empiric therapy’ approach in which CisPem was continued for four cycles before start 
of a tyrosine kinase inhibitor (TKI).   
Results 
The incremental cost-effectiveness ratio (ICER) for ‘Test-treat’ compared to treatment 
with CisPem was $150,000 per quality-adjusted life year (QALY) gained.  Both empiric 
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treatment approaches had less favorable ICERs.  ‘Test-treat’ and ‘Empiric switch 
therapy’ yielded higher expected outcomes in terms of QALYs and life-years (LYs) than 
‘Empiric therapy’.  These results were robust across plausible ranges of model inputs. 
Conclusion 
From a societal perspective, our cost-effectiveness results support the value of 
multiplexed genetic screening and molecularly guided therapy in metastatic NSCLC. 
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3.2 Introduction 
The expansion of targeted therapeutic options for metastatic NSCLC is a 
welcome advance in a disease that historically has been resistant to treatment.  Of the 
estimated 230,000 incident lung cancer cases annually, approximately 85% are 
diagnosed with NSCLC.[1, 2]   Most patients present with advanced disease, and 
adenocarcinoma is the most common histologic subtype. [2]   Somatic mutations in 
EGFR and ALK gene rearrangements are found in 9.5% and 3.9% of unselected 
NSCLCs, respectively.[3]   Patients whose tumors carry a sensitizing mutation of EGFR 
or ALK gene rearrangements experience higher response rates, longer progression-free 
survival (PFS), and improved quality of life when treated with a TKI compared to 
platinum-based doublet chemotherapy.[6-7]  Guidelines recommend the ascertainment 
of EGFR and ALK mutational status to help guide first-line systemic therapy in all 
patients with non-squamous, advanced NSCLC.[8]  According to these 
recommendations, over 130,000 newly diagnosed NSCLC patients each year should 
undergo predictive biomarker screening.[9]  But, biomarker screening appears to be 
underutilized in routine care.  Only 12% of acute-care hospitals in the US used the 
EGFR assay in 2010, which represented only 5.7% of guideline-directed patients. [8, 9]  
Even among patients whose tumors are tested for predictive biomarkers, 
uncertainty surrounding the optimal timing of TKI therapy initiation adds to the 
complexity of treatment decision-making.[10]  The time required to perform molecular 
tests with sufficient tissue for analysis may tip the scale towards commencing empiric 
treatment with chemotherapy.  Once test results reveal the presence of an actionable 
mutation after empiric therapy is begun, indirect evidence suggests that continuation of 
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chemotherapy for four to six cycles before switching to a TKI may optimize 
outcomes.[10, 11] In the present analysis, we compared a number of TKI initiation 
strategies.   
Additionally, turn-around-time (TAT), the time from tissue sample acquisition to 
reporting of test results, and tissue sample adequacy are important considerations in 
patients with metastatic NSCLC.   Multiplex detection of mutations has the advantage of 
tissue preservation and faster TAT. To date, economic analyses of screening for drug 
sensitivity biomarkers in lung cancer have restricted their focus on single 
biomarkers.[12-21]   We examined two molecular markers, EGFR mutations and ALK 
rearrangements, for which the evidence is sufficiently mature to support population-wide 
screening.[8] The goal of this paper was to assess the cost-effectiveness of multiplexed 
predictive biomarker screening from a societal perspective in patients newly diagnosed 
with metastatic NSCLC living in the US.  
3.3 Methods 
3.3.1. Model and Treatment Strategies 
We constructed a microsimulation, state-transition model to estimate the life 
expectancy and costs of four strategies:  a ‘No Test’ approach, treatment with cisplatin-
pemetrexed chemotherapy and no biomarker testing; two different empiric treatment 
strategies in which cisplatin-pemetrexed was initiated with concurrent biomarker testing. 
In one, the ‘Empiric therapy’ strategy, chemotherapy was continued for four cycles 
followed by TKI maintenance treatment in mutation-positive patients. In the other, the 
‘Empiric switch therapy’, patients initiated first-line chemotherapy and those with 
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mutation positive tumors switched to a TKI immediately upon return of test results; and 
finally, the ‘Test-treat’ strategy, in which treatment was initiated only after results of 
testing became available.  The simulated study population comprised of newly 
diagnosed stage IV NSCLC patients with non-squamous histology.  
Figure 3.1 depicts the structure of the model.  For all testing strategies, patients 
entered the model in the prescreen state on the day the test was ordered.  If the sample 
was suitable for testing, the patient transitioned to the test sequence health states.  With 
a daily cycle length, we were able to model wait times for test results prior to initiation of 
therapy.  Patients with insufficient tumor samples from initial diagnostic samples 
transitioned to the rebiopsy prescreen state to account for elapsed time in determining 
appropriateness for a rebiopsy and for performing the procedure.   Patients who did not 
undergo a rebiopsy, or whose rebiopsy samples were inadequate for testing, 
transitioned to the treatment states.  Multiplexed molecular testing proceeded according 
to a two-step test sequence: concurrent EGFR mutation and ALK overexpression 
assays followed by ALK FISH confirmation for ALK IHC positive results (1+, 2+, or 
3+).[8]  Mortality risk in the above health states was modeled based on the natural 
history of advanced NSCLC for the ‘Test-treat’ approach, and first-line cisplatin-
pemetrexed therapy for the empiric treatment strategies.   
Patients in the ‘No test’ strategy entered the model in the first-line cisplatin-
pemetrexed treatment state (Figure 3.1). Upon progression on each therapy, patients 
transitioned to the next line of therapy based on treatment conditional disease risk of 
progression.  Treatment sequences for the other strategies (Table 3.1) followed the 
same model structure.   
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Figure 3.1.  Model structure depicting health states and transitions. 
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Table 3.1 Strategies. 
*CisPem therapy was administered for up to 4 cycles; upon progression on CisPem,
patients transitioned to the next line of therapy 
†TKI maintenance treatment was initiated in presence of drug-sensitizing mutations 
upon completion of 4 cycles of CisPem 
¶Patients with drug-sensitizing mutations switched to a TKI at time of test results after 
receiving one cycle of empiric CisPem therapy 
Abbreviations: CisPem, cisplatin and pemetrexed doublet; Pem, pemetrexed; DTX, 
docetaxel; Erlot, erlotinib; BSC, best supportive care; Criz, crizotinib; ALK, anaplastic 
lymphoma kinase; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; 
For the main analysis, we chose a time horizon of two years to capture the major 
health and economic consequences in metastatic NSCLC.  This duration obviated the 
need for projecting survival outcomes beyond the primary clinical trial data.[22]  Benefits 
Strategy Test Treatment 
No test None CisPem* ► Pem ► DTX ► Erlot ►BSC 
Empiric 
therapy† 
EGFR/ALK IHC ► 
ALK FISH for ALK IHC 1-3+ 
Empiric CisPem x 4 cycles ► test result conditional treatment: 
   EGFR +:    Erlot ► DTX ► BSC 
   ALK +:       Criz  ► DTX ► BSC 
   Other:        CisPem* ► Pem ► DTX ► Erlot ►BSC 
Empiric- 
switch 
therapy¶
EGFR/ALK IHC ► 
ALK FISH for ALK IHC 1-3+ 
Empiric CisPem x 1 cycle ► test result ► test result 
conditional treatment: 
  EGFR +:    Erlot ► CisPem* ► DTX ► BSC 
  ALK +:       Criz  ► CisPem* ► DTX ► BSC 
  Other:       CisPem* ► Pem ► DTX ► Erlot ►BSC 
Test-
treat 
EGFR/ALK IHC ► 
ALK FISH for ALK IHC 1-3+ 
EGFR +:  Erlot ► CisPem* ► DTX ►BSC 
ALK +:     Criz  ► CisPem* ► DTX ►BSC 
Other:      CisPem* ► Pem ► DTX ►Erlot ► BSC 
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and costs were discounted at 3% per annum. Analyses were performed in TreeAge Pro 
2013 (TreeAge Software, Inc.; Williamstown, MA). 
3.3.2. Natural History 
We used data from Surveillance, Epidemiology, and End Results (SEER)-
Medicare to model the natural history of untreated, metastatic NSCLC for simulated 
patients who were awaiting molecular test results. Predicted probabilities from a Cox 
proportional hazards (PH) model for incident SEER cases with Stage IV NSCLC and a 
pathologic diagnosis of non-squamous histology, aged 66-69 years old with diagnoses 
between 2007 and 2009, who were managed with BSC were generated.  The model 
was weighted using the inverse conditional probability of exposure to chemotherapy to 
balance observable covariates between treatment naïve and chemotherapy treated 
patients.  Time dependent transitional probabilities for the simulation model were 
calibrated to the predicted survival probabilities from the Cox PH model using a 
piecewise-exponential approach. 
3.3.3. Clinical Outcomes 
Randomized trials (RCTs) for initiation and maintenance therapy with erlotinib 
and crizotinib in EGFR mutation and ALK rearrangement positive patients, respectively, 
were identified for calculating treatment-conditional progression and survival estimates.  
Efficacy data for other therapies were pulled from RCTs that enrolled molecularly 
unselected patients. The trial-based median estimates for treatment-specific overall 
survival (OS) and PFS were used as calibration targets.  Transition probabilities were 
calculated using a constant hazard assumption.  
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3.3.4. Quality of Life 
We estimated utilities based on a mixed model, which included parameters for 
best tumor response and toxicities commonly encountered with chemotherapy 
treatments in NSCLC (neutropenia, febrile neutropenia, fatigue, diarrhea, nausea and 
vomiting, rash and hair loss).[23]  We used rates for best tumor response, and grade 3 
and 4 adverse drug events (ADEs) from RCTs to calculate treatment-specific utilities 
based on the mixed model (Table 3.2).[23]  Disutilities for ADEs were incorporated in 
the first month of therapy.[14, 24] 
3.3.5. Genomic Markers 
Prevalence rates of biomarkers were drawn from a population-based registry 
(Table 3.2) of 10,000 NSCLC patients who were enrolled for routine screening of 
predictive biomarkers.[3] The cumulative TAT for test results is congruent with 
guidelines, which recommend that EGFR and ALK testing both be completed within 10 
working days of receiving the specimen in the laboratory.[8]  
We estimated that 30% of patients would undergo a rebiopsy and 85% of repeat 
biopsies would yield adequate samples for molecular testing.[13]  The distribution of 
repeat biopsy techniques (bronchoscopic, or transthoracic needle aspiration of primary 
cancer, and metastatic site needle aspirations) and pneumothorax complication rates 
were based on a prior analysis.[13]   
We used ALK FISH positivity as the reference standard for presence of ALK 
rearrangements.[7, 8]   Estimates for IHC test performance were taken from the largest 
published case series evaluating a novel 5A4 monoclonal antibody (Table 3.2). [25]  
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Table 3.2 Model parameters and ranges for sensitivity analyses. 
Variable Base Case Low High Source 
Overall survival, months 
Cisplatin plus pemetrexed 
Pemetrexed  
Docetaxel  
Erlotinib  (1st line) 
Erlotinib (maintenance)* 
Crizotinib  
Erlotinib (3rd line) 
Best supportive care  
Progression-free survival, months 
Cisplatin plus pemetrexed 
Pemetrexed  
Docetaxel  
Erlotinib (1st line) 
Erlotinib (maintenance) 
Crizotinib  
Erlotinib (3rd line) 
11.8 
13.9 
8.0 
19.3 
24.0 
20.3 
6.7 
4.5 
5.3 
4.1 
3.3 
9.7 
10.3 
7.7 
2.2 
10.4 
12.8 
6.4 
14.7 
19.2 
18.1 
5.5 
4.3 
4.8 
3.2 
2.6 
8.4 
8.2 
6.0 
1.9 
13.2 
16.0 
9.6 
26.8 
28.8 
26.8 
7.8 
4.9 
5.7 
4.6 
4.0 
12.3 
12.4 
8.8 
2.8 
[37] 
[38] 
[16] 
[39] 
[40] 
[7] 
[41] 
SEER-
Medicare 
[37] 
[38] 
[16] 
[39] 
[40] 
[7] 
[41] 
Health State Utilities  
With best response and adverse events 
Cisplatin plus pemetrexed 
Pemetrexed  
Docetaxel  
Erlotinib (1st line) 
Erlotinib (maintenance) 
Crizotinib  
Erlotinib (3rd line) 
No treatment   
With best response and no adverse 
events 
Cisplatin plus pemetrexed 
Pemetrexed  
Docetaxel  
Erlotinib (1st line) 
Erlotinib (maintenance) 
Crizotinib  
Erlotinib (3rd line) 
0.59 
0.60 
0.48 
0.64 
0.66 
0.64 
0.56 
0.46 
0.62 
0.60 
0.57 
0.65 
0.66 
0.66 
0.59 
0.51 
0.54 
0.37 
0.58 
0.61 
0.58 
0.49 
0.36 
0.56 
0.55 
0.51 
0.60 
0.61 
0.60 
0.53 
0.66 
0.65 
0.59 
0.70 
0.71 
0.70 
0.64 
0.55 
0.67 
0.66 
0.64 
0.71 
0.71 
0.71 
0.65 
[23, 37] 
[23, 38] 
[16, 23] 
[23, 39] 
[23, 40] 
[7, 23] 
[23, 41] 
[23] 
[23, 37] 
[23, 38] 
[16, 23] 
[23, 39] 
[23, 40] 
[7, 23] 
[23, 41] 
Probabilities (%) 
EGFR mutation positive 
ALK rearrangement positive 
Inadequate tissue – initial 
biopsy 
Re-biopsy  
Inadequate tissue - re-biopsy 
ALK IHC specificity 
ALK IHC sensitivity 
9.5 
3.9 
37.7 
30 
15 
96 
100 
8.9 
3.5 
26 
15 
10 
95 
100 
10.7 
4.3 
49 
45 
25 
100 
100 
[3] 
[3] 
[42] 
Expert opinion 
[13] 
[25] 
[25] 
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Table	  3.2 (continued)	  
*probability of survival = 0.6; median survival probability not reported
†includes time for delivery of tissue sample to the laboratory 
 Abbreviations: ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; FISH, fluorescence in situ 
hybridization; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; FISH, fluorescence in situ 
hybridization; TAT, turnaround time from receipt of specimen to report of test results. 
Turnaround time (TAT), days† 
With no re-biopsy 
With re-biopsy 
12 
24 
7 
13 
16 
34 
[8],Expert 
Opinion 
Costs, 2013 US$ 
EGFR mutation assay 
ALK IHC assay 
ALK FISH assay 
Cisplatin and pemetrexed 
Drug acquisition  (per 21 day cycle) 
Premedication  
Administration, monitoring 
Adverse drug event treatment 
Pemetrexed maintenance 
Drug acquisition  (per 21 day cycle) 
Premedication  
Administration, monitoring 
Adverse drug event treatment 
Docetaxel 
Drug acquisition  (per 21 day cycle) 
Premedication  
Administration, monitoring 
Adverse drug event treatment 
Erlotinib 
Drug acquisition  (per 21 day cycle) 
Premedication  
Administration, monitoring 
Adverse drug event treatment 
1st line 
3rd line 
Maintenance 
Crizotinib 
Drug acquisition  (per 21 day cycle) 
Premedication  
Administration, monitoring 
Adverse drug event treatment 
Disease progression, per month 
Patient time, per hour 
Travel, per 30 mile round trip 
$201 
$136 
$489 
$5,721 
$254 
$446 
$760 
$5,689 
$6 
$276 
$304 
$937 
$8 
$329 
$2,525 
$3,982 
$0 
$165 
$358 
$727 
$358 
$8,041 
$0 
$165 
$550 
$5,457 
$19 
$15 
$201 
$136 
$489 
$4,577 
$203 
$357 
$608 
$4,551 
$5 
$221 
$243 
$750 
$6 
$263 
$2,020 
$3,186 
$0 
$132 
$286 
$582 
$286 
$6,433 
$0 
$132 
$440 
$5,283 
$10 
$8 
$718 
$217 
$598 
$6,865 
$305 
$535 
$912 
$6,827 
$7 
$331 
$365 
$1,124 
$10 
$395 
$3,030 
$4,778 
$0 
$198 
$430 
$872 
$430 
$9,649 
$0 
$198 
$660 
$5,605 
$29 
$23 
[43, 44] 
[43, 44] 
[43, 44] 
[45] 
[45, 46] 
[43, 44] 
[43-47] 
[45] 
[45, 46] 
[43, 44] 
[43-47] 
[45] 
[45, 46] 
[43, 44] 
[43-47] 
[46] 
[45, 46] 
[43, 44] 
[43-47] 
[43-47] 
[43-47] 
[46] 
[45, 46] 
[43, 44] 
[43-47] 
[26] 
[48] 
[49] 
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3.3.6. Costs 
Cancer-related medical costs, costs of travel and patient time spent seeking 
medical care were included in the model (Table 3.2).   We used the Centers for 
Medicare and Medicaid Services (CMS) reimbursement rates for each biomarker assay 
in our base case analysis, and for other direct medical costs, including drug 
administration, imaging and ADEs.   Costs for treatment specific ADEs were assumed 
to accrue in the first month of therapy.[14, 24]   The average sale price (ASP) and 
average wholesale price (AWP) were used to value injectable and orally administered 
drugs, respectively.   With the exception of cisplatin-pemetrexed chemotherapy, which 
was administered up to four cycles, patients were assumed to accrue drug-related costs 
up to the time of progression.  Costs for rebiopsy and related complications were 
derived from the analysis by Handorf, et al.[13] The cost for treating progressive 
disease was based on lung cancer attributable costs in the last year of life.[26]  All costs 
in the model were adjusted to 2013 values using the GDP deflator series.[27]   
3.3.7. Cost Effectiveness Analysis 
We calculated the incremental cost-effectiveness by ranking the strategies in 
order of increasing effectiveness.  Strongly dominated strategies, those that had a 
lower, or equal effectiveness and higher costs, were eliminated.  Incremental cost 
effectiveness ratios (ICERs) were calculated for each strategy in relation to the next 
best strategy.  The ICER is a ratio of the difference in mean costs divided by the 
difference in mean QALYs.  Strategies with a higher ICER that were less effective than 
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another strategy were eliminated by extended dominance.  The ICERs were 
recalculated for the remaining non-dominated strategies.[28]  
3.3.8. Sensitivity Analyses 
We conducted sensitivity analyses to evaluate which parameters were most 
influential on model results.  Where available, the ranges used for the parameters 
corresponded to the 95% CIs (Table 3.2).  Costs were varied ±20% and plausible 
ranges for TATs were used based on expert opinion.   We also simulated the lifetime (5 
year) costs and effectiveness where prognosis beyond trial observation period was 
modeled using exponential distributions.  Additionally, model outputs were generated 
based on commercial prices for molecular assays.  Finally, we ran a sensitivity analysis 
for the transition probability of dying while awaiting test results based on treatment 
naïve patients who were randomized to best supportive care (BSC) in a RCT.[29] 
3.4 Results 
Multiplexed testing approaches of ‘Test-treat’ and ‘Empiric switch’ were most 
effective (Table 3.3).  Both yielded an average life expectancy of 0.97 life years (LY), 
and 0.56 QALYs.  The ‘Empiric therapy’ approach, in which chemotherapy was 
continued for four cycles before initiation of molecularly guided therapy, was less 
effective (0.95 LY and 0.55 QALYs). Because the ‘Empiric switch’ approach was more 
expensive than the ‘Test-treat’ strategy (but equally effective), it was ruled out by strong 
dominance.  The ‘Empiric therapy’ approach was eliminated by extended dominance 
since it was associated with a higher ICER than the ‘Test-treat’ approach.  Compared 
with the ‘No test’ strategy, the ‘Test-treat’ approach of concurrent EGFR mutation and 
ALK IHC testing followed by ALK FISH confirmation prior to initiation of any therapy  
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Table 3.3  Cost Effectiveness Results. 
Abbreviations: LYs, life-years; QALYs, quality-adjusted life-years; ICER, incremental cost 
effectiveness ratio;  
*costs and life expectancy outcomes discounted at 3% annual rate   †2013 $US
yielded an ICER of $150,000 per additional QALY.  Without adjustment for quality of life, 
the ‘Test-treat’ approach had an ICER of $98,000 per LY gained compared to the ‘No 
test’ strategy. 
3.4.1. Sensitivity Analyses 
Changing the parameters values over ranges listed in Table 3.2 did not impact 
the rank order of the strategies.  Also, both empiric treatment strategies remained 
dominated.  A comparison of the non-dominated strategies revealed that the most 
influential parameters were utilities and acquisition costs for TKIs (Figure 3.2).  We 
found that the ICER for the ‘Test-treat’ approach compared to the ‘No test’ strategy 
ranged from $138,000 to $171,000 per additional QALY, with high and low utility values, 
respectively; and from $97,000 to $204,000 per QALY gained when the TKI acquisition 
costs were varied by minus and plus 20%, respectively.  In all other scenarios, the ICER 
for ‘Test-treat’ compared to ‘No test’ ranged from $120,000 to $160,000 per QALY.  
Strategy* LYs QALYs Cost† 
ICER 
($/LY) 
ICER 
($/QALY) 
Standard Care: No test, 
chemotherapy alone 0.93 0.53 $79,331 - - 
Empiric Therapy 0.95 0.55 $82,762 Extended Dominance 
Extended 
Dominance 
Empiric Switch Therapy 0.97 0.56 $86,645 Dominated Dominated 
Test-Treat 0.97 0.56 $83,413 98,000 150,000 
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Figure 3.2.  Sensitivity analyses.  Tornado diagram of influential parameters on the 
incremental-cost effectiveness ratio (ICER) of ‘Test-treat’ vs. ‘No Test’ strategies.   
Test-treat vs. Test 
ICER ($/QALY) 
TKI, tyrosine kinase inhibitor; ALK, anaplastic lymphoma kinase rearrangement; EGFR, 
epidermal growth factor drug sensitizing mutation; TAT, turn-around time; BSC, best-
supportive care; IHC, immunohistochemistry; QALY, quality-adjusted life year. 
80,000  100,000  120,000  140,000  160,000  180,000  200,000  220,000  
Probability of rebiopsy 
ALK IHC test specificity 
Cost of BSC 
TAT 
EGFR mutation frequency 
Probability of adequate initial tissue sample 
Discount rate 
ALK rearrangement frequency 
Probability of progression and mortality with 
therapy 
Utilities 
TKI price 
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Commercial prices for assays had a small effect on the ICER ($167,000 per 
QALY for the ‘Test-treat’ vs. ‘No test’ strategy).  Extrapolation of long-term survival 
lowered the ICER for ‘Test-treat’ to $148,000 compared to ‘No Test’.  With a trial-based 
mortality risk in the pre-treatment health states (using a piecewise exponential model 
with survival probabilities of 97% and 90% at 1 and 2 months after diagnosis, 
respectively), the same dominance pattern was observed and the ICER remained stable 
for the ‘Test-treat’ strategy compared to ‘No Test’ ($153,000/QALY).[29]  
Varying the proportion of patients for whom multiplexed molecular testing is 
ordered showed that decreasing this proportion to 5%, from 100% in the base-case 
analysis, would lower the outcomes in terms of expected QALYs to 0.54 for all testing 
strategies.  Both empiric treatment strategies would still be dominated, and the ICER for 
‘Test-treat’ compared to the ‘No test’ strategy would be $166,000/QALY.[9]  
3.5 Discussion 
Concurrent EGFR mutation and ALK IHC testing with ALK FISH confirmation for 
tumors that overexpress the ALK protein prior to initiation of therapy yielded an ICER of 
$150,000 per QALY gained compared to no testing and treatment with chemotherapy 
alone.   Whether or not an ICER of $150,000 provides good value is contingent upon 
the willingness-to-pay threshold, which serves as a guide of how much society is willing 
to pay for an additional QALY. The World Health Organization (WHO) defines 
interventions with ICERs within three times the GDP per capita as being cost effective 
($155,000 in the US). [30]    Others posit that a threshold of $200,000 per QALY may be 
more appropriate based on empirical data of ICERs for commonly used 
interventions.[31, 32]  Using these benchmarks, our results suggest that multiplexed 
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testing followed by molecularly guided therapy in metastatic NSCLC provides good 
value from a societal perspective. 
Our simulation study confirms that waiting for test results prior to initiation of 
treatment optimizes outcomes in newly diagnosed patients with metastatic NSCLC.[10]  
While empiric therapy in which chemotherapy is initiated concurrently with testing for 
mutations, followed by an immediate switch to molecularly guided therapy at the time 
test results become available yielded the same life expectancy as the test then treat 
approach, the former strategy was dominated since it was more expensive.  
Continuation of empiric chemotherapy for four cycles before switching to test-result 
conditional treatment yielded less favorable outcomes than the above two approaches, 
both in terms of QALYs and LYs.  This strategy was eliminated by extended dominance. 
These results were robust to variations over plausible ranges of model parameters. 
In sensitivity analyses, the ICER was highly sensitive to drug acquisition costs.  
At lower TKI prices, (80% of brand name product price), the ICER for the ‘Test-treat’ 
strategy decreased to $97,000/QALY compared to standard treatment with 
chemotherapy.  Over time, once generic versions of TKIs become available, these 
innovations will confer even better value.  The optimal price point that maximizes social 
welfare, while minimizing the impact on technological innovation, is outside the scope of 
this analysis.  However, growing concerns over the increasing cost burden of these 
innovations on patients deserve scrutiny.[33-35]  Patient access to these drugs may be 
impeded by onerous out of pocket costs.  One way to attenuate the impact of cost 
sharing may be through value based benefit design.  Arguably, breakthrough therapies 
that offer substantial improvement in outcomes and are placed into lower cost sharing 
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tiers would benefit society as a whole from healthier patients who remain productive, as 
they are able to access these beneficial treatments.   
We were unable to identify published economic analyses that examined 
multiplexed testing in advanced NSCLC. Handorf, et al. evaluated the cost effectiveness 
of molecularly guided first-line therapy using EGFR mutation testing in the US from a 
payer perspective. The ICERs for testing with and without rebiopsy and EGFR mutation 
guided treatment ranged from $110,644 to $122,219 per QALY gained compared to 
treatment with a carboplatin-paclitaxel doublet.[13]   Similar to our analysis, the cost-
effectiveness results from that study support the value of molecularly guided therapy.  
Another recently published study examined the cost-effectiveness of ALK 
rearrangement testing alone prior to first-line crizotinib treatment in ALK-positive tumors 
or cisplatin-gemcitabine combination chemotherapy in wild type tumors.[21]  From a 
Canadian public health perspective, that analysis generated an ICER of $255,970 per 
additional QALY for molecularly guided therapy compared to chemotherapy.  The 
authors concluded that genetic testing and treatment with molecularly guided therapy 
was not cost-effective.  Several differences between our analysis and the Canadian 
study are worth noting.  First, we combined multiplexed testing in our analysis, which de 
facto produces better outcomes for the molecular testing strategy since more patients 
benefit from testing.  Second, in our analysis, the mean life expectancy with doublet 
chemotherapy using a lifetime horizon was 12.2 months, an estimate that is identical to 
a separate analysis we conducted based on SEER-Medicare patients with newly 
diagnosed Stage IV NSCLC (data not shown).  On the other hand, Djalalov et al. 
reported a mean life expectancy of 7.4 months in patients who initiated therapy with 
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first-line cisplatin and gemcitabine.[21]  Third, our utility weights were appreciably higher 
for crizotinib and some other overlapping treatments, such as third-line erlotinib therapy. 
These differences in part explain the disparities in our respective studies.  
Our results are subject to modeling assumptions and need to be interpreted in 
this context.   For example, due to treatment crossover after progression and lack of 
direct comparisons in RCTs, we relied on single-arm data for our parameters.  
Furthermore, we used data from PROFILE 1007, a phase 3 RCT of second-line 
crizotinib, to inform hazard rates in our model for OS and PFS.[7] These estimates 
apply to a small subset of patients in our model, those with ALK rearrangement positive 
status.  Any bias introduced into the model would thus be marginal given the size of this 
subgroup.[36]   Overall, varying the hazard rates for treatment effects in sensitivity 
analyses revealed that the base case results were robust to these assumptions.  Also, 
we used Medicare reimbursements as a proxy for the societal costs of test assays.  
However, the true costs of the tests may vary across providers.  But even with 
commercial test prices, the ICER for the ‘Test-treat’ compared to the ‘No test’ strategy 
increased to $167,000 per additional QALY, which is still below commonly acceptable 
willingness-to-pay thresholds.[31] 
In summary, our analysis suggests that multiplexed testing for EGFR mutations 
and ALK overexpression with an IHC assay followed by ALK rearrangement 
confirmation with FISH for IHC positive results and biomarker conditional treatment is a 
cost effective strategy compared to treatment with chemotherapy and no testing in 
metastatic NSCLC.   Empiric cisplatin-pemetrexed therapy for four cycles with 
concurrent molecular testing prior to initiation of TKI maintenance therapy generated 
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inferior outcomes compared to waiting for test results before treatment, and compared 
to ‘Empiric switch therapy’ in which chemotherapy initiated treatment was immediately 
switched to molecularly guided therapy when test results became available. 
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3.7 Appendix 
3.7.1 Natural History 
To model the natural history of untreated advanced NSCLC while simulated 
patients were awaiting molecular marker test results and for those in the BSC strategy, 
we used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked 
database to identify incident cases of advanced NSCLC patients with pathologic 
diagnosis of non-squamous histology, aged 66-69 years old, who were diagnosed 
between 2007 and 2009.  The SEER population-based registries, which represent 28% 
of the US population, provide a rich repository of data related to tumor characteristics 
and prognosis.[7] The patient-level linked Medicare data (CMS) provide claims 
information for fee-for-service (FFS) coverage for services provided in hospitals, 
outpatient clinics, physician encounters, durable medical equipment, hospice, home 
health care and prescription medications covered by Medicare Part D plans.   We used 
predicted probabilities from a Cox model probability weighted using the inverse 
conditional probability of exposure to systemic therapy to balance observable covariates 
between treatment naïve and treated patients.  Time dependent transitional probabilities 
for the simulation model were calibrated to the predicted survival probabilities from the 
Cox model using a piecewise-exponential approach. 
Patients with Stage IV NSCLC who were diagnosed during 2007-2009 were 
identified form the SEER database.  Further inclusion criteria included: age 66 to 69 (the 
ages were selected to parallel the median ages reported in the clinical trials which were 
used for treatment efficacy estimates); non-squamous histology (adenocarcinoma, large 
cell, NOS; BAC histology was excluded from the analysis); first and only cancer 
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diagnosis; continuous enrollment in FFS.  The minimum follow up was 12 months after 
diagnosis.  Classification into the systemic treatment group was based on any claim for 
systemic therapy (in hospital, physician, outpatient, Medicare D, home health care and 
durable equipment claims files) within 60 days of diagnosis.   To ensure that patients 
included in the analysis were representative of those who would be candidates for 
systemic therapy, we matched patients based on 39 characteristics, which included 
proxy indicators for performance status at diagnosis (2 variables: claims for home 
oxygen therapy and claims for activity of daily living aids).  (We would like to thank Dr. 
Lamont for providing us with the algorithm for the performance status indicators).   
A propensity score logistic regression model was estimated, using receipt of 
systemic therapy as the outcome variable and the above variables that may affect 
treatment selection as the covariates.  Inverse propensity score weighting (IPW) was 
used to assess the balance in baseline characteristics.  All standardized differences for 
IPW weighted analyses of each covariate between the treatment groups were less than 
0.10 indicating the groups were well balanced on baseline characteristics (Table 3.A.1) 
across treatment groups among the 11,443 included patients.   
102	  
Table  3.A.1. Baseline characteristics among Stage IV NSCLC patients by treatment 
group. 
Unweighted means Weighted means 
Systemic 
therapy 
N=5050 
% 
BSC 
N=6393 
% 
Standardized 
Difference 
Systemic 
Therapy 
N=5050 
% 
BSC 
N=6393 
% 
Standardized 
Difference 
Female 48 51 0.057 50 50 0.001 
Age 
66-69 
70-74 
75-79 
80-84 
85+ 
25 
30 
25 
15 
5 
17 
23 
23 
21 
16 
0.208 
0.171 
0.035 
0.154 
0.381 
21 
26 
24 
18 
11 
20 
26 
24 
18 
11 
0.004 
0.006 
0.001 
0.003 
0.006 
Race 
Hispanic 
White 
Black 
Other race 
4 
82 
7 
8 
4 
80 
9 
7 
          0.017 
0.050 
0.081 
0.023 
4 
80 
8 
8 
4 
80 
8 
7 
0.004 
0.005 
0.003 
0.008 
Marital status 
Single 
Married 
Unknown 
7 
58 
35 
9 
44 
47 
0.060 
0.284 
0.255 
8 
51 
42 
8 
51 
41 
0.005 
0.000 
0.003 
Median household income in census tract $50,515 $48,105 0.107 $49,067 $49,066 0.000 
Proportion with college degree in census 
tract 25.3 24.1 0.072 24.5 24.6 0.047 
Gagne comorbidity score 
0 
1 
2 
3+ 
67 
16 
8 
9 
59 
17 
9 
15 
0.184 
0.035 
0.038 
0.201 
62 
17 
8 
13 
62 
17 
8 
12 
0.012 
0.000 
0.000 
0.018 
Histology 
Adenocarcinoma 
Large cell 
BAC 
NOS 
56 
5 
2 
37 
56 
5 
2 
37 
0.004 
0.020 
0.001 
0.013 
56 
5 
2 
37 
56 
5 
2 
37 
0.003 
0.000 
0.002 
0.003 
Brain metastases 16 21 0.137 19 19 0.002 
MDs in county, (per 100,000) 238.5 240.1 0.012 238.1 239.5 0.081 
Hospital beds in county, (per 100,000) 320.9 322.2 0.006 323.7 320.2 0.131 
Managed care penetration (%) 19.7 20.6 0.071 20.2 20.3 0.020 
Foreign born (%) 13.0 12.9 0.009 13.0 12.9 0.038 
Hospital days pre dx  3.0 4.8 0.224 4.3 4.1 0.108 
Home health care enrolment pre dx 8 14 0.217 12 11 0.021 
SNF enrolment pre dx 3 8 0.233 6 6 0.002 
Pre-diagnosis costs, within 1 year of 
diagnosis, mean (SD) $6,884 $10,053 0.172 $8,985 $8,752 0.080 
State buy-in 16 21 0.133 19 19 0.004 
Alcohol abuse 0 1 0.037 1 1 0.000 
CHF 9 13 0.136 11 11 0.016 
Cardiac arrhythmias 11 15 0.115 14 13 0.014 
Chronic pulmonary disease 22 25 0.083 24 24 0.009 
Coagulopathy 2 2 0.005 2 2 0.014 
Complicated diabetes 5 6 0.048 6 6 0.008 
Deficiency anemias 11 14 0.089 13 12 0.009 
Dementia 1 3 0.153 2 2 0.007 
Fluid and electrolyte dis 4 8 0.140 7 6 0.012 
HIV/AIDS 0 0 0.003 0 0 0.008 
Hemiplegia 0 1 0.064 0 0 0.005 
Hypertension 53 52 0.023 53 52 0.010 
Liver disease 13 15 0.037 14 14 0.009 
Peripheral vascular disor 11 15 0.129 13 13 0.011 
Psychosis 2 3 0.077 3 2 0.005 
Pulmonary circulation dis 1 2 0.043 1 1 0.001 
Renal failure 4 7 0.123 6 6 0.013 
Weight loss 0 1 0.092 1 1 0.031 
COPD ER/hosp prior to diagnosis 2 3 0.081 2 2 0.011 
Home Oxygen Therapy Aids 15 18 0.076 18 17 0.016 
ADL Aids 7 11 0.141 10 10 0.016 
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3.7.2 Survival Analysis 
Non-parametric Kaplan-Meier survival curves are useful in characterizing the 
survival function and do not require any distributional assumptions, however, 
adjustment for confounding using IPW is not feasible with this approach.  We thus 
pursued both semi-parametric models (Cox model) and parametric models (exponential, 
Weibull, generalized gamma, log-logistic and log-normal) to adjust for IPW.  Models 
were fit with treatment indicator as the sole covariate and weighted using the IPW.  All 
models were analyzed using SAS (version 9.3).  Goodnness-of-Fit statistics using the 
corrected Akaike information criterion (AICc) were used to compare the fit of the hazard 
function across models.   The Cox model was associated with the lowest AICc value 
and was thus deemed to have the best fit to the data. 
Furthermore, to attenuate survivor treatment selection bias, we opted to express 
the treatment variable as a time-dependent covariate in the Cox PH model. (6)  The 
predicted survival probabilities from the Cox PH models and the calibrated probabilities 
from the simulation model are shown below.  Time dependent transitional probabilities 
for the simulation model were calibrated to the Cox predicted survival probabilities using 
a piecewise-exponential approach. 
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Figure 3.A.1. Natural history model calibration. 
 
Top panel: The overall predicted survival probabilities from Cox PH models for systemic therapy and 
treatment naïve groups (green and blue lines, respectively) are shown.  Predictions from separate 
specifications of Cox PH models are shown: solid lines correspond to estimates  with treatment as a fixed 
covariate; dashed lines correspond to time-varying treatment covariate specification.  Bottom panel: Red 
curve represents the calibrated survival probability curve from the simulation model; dashed blue line 
corresponds to the predicted survival probabilities for treatment naïve group with chemotherapy as a 
time-varying covariate; grey curves correspond to the 96% CI.  All Cox PH model results are inverse 
probability weighted for propensity to receive systemic therapy within 60 days from diagnosis.	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3.7.3 Treatment Conditional Outcomes 
The model simulated progression-free and overall treatment conditional survival 
using exponential models.  Studies that met inclusion criteria for estimation of these 
efficacy parameters comprised of phase 3 randomized trials. With the exception of first-
line crizotinib and switch maintenance erlotinib, we were able to identify studies for all 
other lines of treatment that met the inclusion criteria.  The PROFILE 1007 trial 
evaluated the efficacy of crizotinib in the second line treatment.[9]  The PROFILE 1014 
trial is currently enrolling patients in the first line setting, but the results will not be 
available for some time (personal communication, Dr. Shaw).   There is an ongoing 
debate about the consistency of outcome results with targeted therapies between first 
and second line therapy given no direct comparisons of the two approaches.[10]  
Indirect comparisons suggest relatively better outcomes in first line setting compared to 
second line, but the evidence is based on retrospective analyses or small sample sizes. 
The use of PROFILE 1007 results in the first line setting in our model  applies to a small 
subset of patients with ALK rearrangement positive status (<5%).  Any bias introduced 
into a model would thus be marginal given the size of the subgroup and it would be in 
favor of the standard care strategy. 
The median estimates from trials were used as the calibration targets.  The 
hazard rates were changed iteratively to approximate the arm-specific median survival 
estimates from eligible trials.   
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Table 3.A.2. Calibration results of simulation model parameters compared with 
randomized trials. 
Variable Trial Simulation 
Overall survival, months 
Cisplatin plus pemetrexed 11.8 11.8 
Pemetrexed 13.9 13.9 
Erlotinib  (1st line) 19.3 19.3 
Erlotinib (maintenance) 24.0 23.8 
Crizotinib 20.3 20.2 
Erlotinib (3rd line) 6.7 6.6 
Docetaxel 8.0 7.9 
Best supportive care (4th 
line) 
4.6 4.6 
Progression-free survival, months 
Cisplatin plus pemetrexed 5.3 5.3 
Pemetrexed 4.1 4.1 
Erlotinib  (1st line) 9.7 9.6 
Erlotinib (maintenance) 10.3 10.3 
Crizotinib 7.7 7.6 
Erlotinib (3rd line) 2.2 2.2 
Docetaxel 3.3 3.4 
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Figure 3.A.2.  Calibration of treatment conditional survival curves.   
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Figure 3.A.2.  (continued) 
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Figure 3.A.2.  (continued) 
Model predicted survival probabilities (grey curves) are juxtaposed with survival 
probabilities from randomized clinical trials included in the model (diamonds).    Non-
solid curves correspond to model predictions that extend beyond the analytical time.  
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3.7.4  Best Response and Adverse Drug Event Rates 
Best response rates (CR/PR, SD, PD) were pulled from the randomized trials 
that we included for efficacy endpoints.  Prevalence of grade 3 and 4 adverse drug 
events (ADE) were obtained from the same trials (Table 3.A.3).  ADE and best 
response frequencies were assumed to be fixed in our model. 
Table 3.A.3.  Best response and adverse event probabilities by treatment. 
3.7.5 Utilities 
Treatment specific utilities were calculated based on the prediction model 
reported by Nafees et al. (Table 3.A.4).[11]  Time spent in each health state was 
weighted by a utility for that state to estimate QALYs.  Utilities were drawn from a 
community-based study in advanced NSCLC from the UK.[11] The authors elicited 
societal based utility values from 100 participants of the general community using the 
standard gamble approach.  The predictive model for health state utilities generated by 
the authors is shown in Table 3.A.4.  The model was a function of tumor progression 
Therapy* Erlotinib 
1st line 
Crizotinib Erlotinib 
maintenance 
Cisplatin/ 
pemetrexed 
Pemetrexed Erlotinib 
3rd line 
Docetaxel 
Source EURTAC PROFILE SATURN Scagliotti PARAMOUNT BR21 meta 
Best 
response 
CR/PR** 0.58 0.66 0.55 0.31 0.03 0.09 0.09 
PD** 0.07 0.06 0.00 0.23 0.28 0.38 0.46 
Grade 3/4 
ADE 
Neutropenia 0.00 0.13 0.00 0.15 0.04 0.00 0.32 
Febrile 
Neutropenia 
0.00 0.01 0.01 0.01 0.01 0.00 0.06 
fatigue 0.06 0.02 0.00 0.07 0.04 0.16 0.28 
N&V 0.00 0.02 0.00 0.13 0.01 0.00 0.26 
diarrhea 0.05 0.00 0.02 0.00 0.00 0.11 0.12 
hair loss 0.00 0.00 0.00 0.12 0.00 0.00 0.38 
rash 0.13 0.00 0.09 0.00 0.00 0.16 0.07 
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state (CR/PR, SD, PD) and grade 3-4 toxicities associated with treatment (neutropenia, 
febrile neutropenia, fatigue, diarrhea, nausea and vomiting, rash and hair loss), domains 
which demonstrated an impact on HRQOL in prior studies.   We calculated utilities 
based on the Nafees model and trial-based best response rates (CR/PR, SD, PD) and 
prevalence rates of grade 3 and 4 adverse drug events (ADEs) (Table 3.A.3).  ADE and 
best response frequencies were treated as fixed values.   Consistent with other reports, 
disutilities for ADEs were incorporated for the first month of therapy while remaining 
months on therapy were weighted using weights calculated using best response rates 
only.[12]  All patients in the BSC health state were assumed to be in the progressive 
state with no additional disutilities based on symptoms. 
Table 3.A.4.  Predictive model of utilities in lung cancer based on best response to 
therapy and adverse events. 
Utility Base 
case 
estimate 
Standard 
error 
Source 
Intercept 0.6532 0.02223 Nafees 2009 
PD -0.1798 0.02169 Nafees 2009 
CR/PR 0.0193 0.006556 Nafees 2009 
Neutropenia -0.08973 0.01543 Nafees 2009 
FN -0.09002 0.01633 Nafees 2009 
Fatigue -0.07346 0.01849 Nafees 2009 
N&V -0.04802 0.01618 Nafees 2009 
Diarrhea -0.0468 0.01553 Nafees 2009 
Alopecia -0.04495 0.01482 Nafees 2009 
Rash -0.03248 0.01171 Nafees 2009 
